201
|
Kalidasan V, Liu XL, Li Y, Sugumaran PJ, Liu AH, Ren L, Ding J. Examining the effect of ions and proteins on the heat dissipation of iron oxide nanocrystals. RSC Adv 2018; 8:1443-1450. [PMID: 35540917 PMCID: PMC9077098 DOI: 10.1039/c7ra11472a] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2017] [Accepted: 11/29/2017] [Indexed: 01/05/2023] Open
Abstract
In this paper, the effect and contribution of physiological components like ions and proteins under an applied alternating magnetic field (AMF) towards heat dissipation of superparamagnetic iron oxide nanoparticles (SPIONs) are discussed. Our results have shown that under an applied AMF, magnetic hyperthermia efficiency could be significantly enhanced if SPIONs were suspended in 1× phosphate buffered saline (PBS) compared to a suspension in de-ionized (DI) water. However, no heat enhancement was found when SPIONs were suspended in blood which is an amalgamation of physiological ions and proteins. Closer investigations have revealed that the presence of physiological ions can contribute positively to heating efficiency, and the heating efficiency increases with concentration of ions, ionic mass and solubility. However, the heating efficiency of ions can be suppressed to an insignificant level (comparable with measurement error), in the presence of physiological proteins in 1×PBS. Our electrochemical studies also showed that ionic mobility can be reduced significantly if proteins were present in the solution, thus retarding the heating efficiency.
Collapse
Affiliation(s)
- V Kalidasan
- Department of Materials Science & Engineering, Faculty of Engineering, National University of Singapore 7 Engineering Drive 1 117574 Singapore
| | - X L Liu
- Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology Beijing 100190 People's Republic of China
| | - Y Li
- Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology Beijing 100190 People's Republic of China .,Department of Biomaterials, Fujian Provincial Key Laboratory of Fire Retardant Materials, College of Materials, Xiamen University Xiamen 361005 People's Republic of China
| | - P J Sugumaran
- Department of Materials Science & Engineering, Faculty of Engineering, National University of Singapore 7 Engineering Drive 1 117574 Singapore
| | - A H Liu
- Department of Materials Science & Engineering, Faculty of Engineering, National University of Singapore 7 Engineering Drive 1 117574 Singapore
| | - L Ren
- Department of Biomaterials, Fujian Provincial Key Laboratory of Fire Retardant Materials, College of Materials, Xiamen University Xiamen 361005 People's Republic of China
| | - J Ding
- Department of Materials Science & Engineering, Faculty of Engineering, National University of Singapore 7 Engineering Drive 1 117574 Singapore
| |
Collapse
|
202
|
|
203
|
Arsalan M, Khan S, Golman J, Szerlip M, Mahoney C, Herbert M, Brown D, Mack M, Holper EM. Balloon aortic valvuloplasty to improve candidacy of patients evaluated for transcatheter aortic valve replacement. J Interv Cardiol 2017; 31:68-73. [PMID: 29285803 DOI: 10.1111/joic.12476] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2017] [Revised: 11/19/2017] [Accepted: 11/20/2017] [Indexed: 11/30/2022] Open
Abstract
OBJECTIVES Evaluate the role of balloon aortic valvuloplasty (BAV) in improving candidacy of patients for transcatheter aortic valve replacement (TAVR). BACKGROUND Patients who are not candidates for TAVR may undergo BAV to improve functional and clinical status. METHODS 117 inoperable or high-risk patients with critical aortic stenosis underwent BAV as a bridge-to-decision for TAVR. Frailty measures including gait speed, serum albumin, hand grip, activities of daily living (ADL); and NYHA functional class before and after BAV were compared. RESULTS Mean age was 81.6 ± 8.5 years and the mean Society of Thoracic Surgeons predicted risk of mortality was 9.57 ± 5.51, with 19/117 (16.2%) patients non-ambulatory. There was no significant change in mean GS post-BAV, but all non-ambulatory patients completed GS testing at follow-up. Albumin and hand grip did not change after BAV, but there was a significant improvement in mean ADL score (4.85 ± 1.41 baseline to 5.20 ± 1.17, P = 0.021). The number of patients with Class IV congestive heart failure (CHF) was significantly lower post BAV (71/117 [60.7%] baseline versus 18/117 [15.4%], P = 0.008). 78/117 (66.7%) of patients were referred to definitive valve therapy after BAV. CONCLUSIONS When evaluating frailty measures post BAV, we saw no significant improvement in mean GS, however, we observed a significant improvement in non-ambulatory patients and ADL scores. We also describe improved Class IV CHF symptoms. With this improved health status, the majority of patients underwent subsequent valve therapy, demonstrating that BAV may improve candidacy of patients for TAVR.
Collapse
Affiliation(s)
| | | | | | | | | | | | - David Brown
- The Heart Hospital Baylor Plano, Plano, Texas
| | | | - Elizabeth M Holper
- Baylor Research Institute, Plano, Texas.,The Heart Hospital Baylor Plano, Plano, Texas
| |
Collapse
|
204
|
Joseph B, Jehan FS. The Mobility and Impact of Frailty in the Intensive Care Unit. Surg Clin North Am 2017; 97:1199-1213. [DOI: 10.1016/j.suc.2017.07.007] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
205
|
|
206
|
Costa C, Teles RC, Brito J, Neves JP, Gabriel HM, Abecassis M, Ribeiras R, Abecasis J, Nolasco T, Furstenau MDC, Vale N, Tralhão A, Madeira S, Mesquita J, Saraiva C, Calé R, Almeida M, Aleixo A, Mendes M. Advantages of a prospective multidisciplinary approach in transcatheter aortic valve implantation: Eight years of experience. Rev Port Cardiol 2017; 36:809-818. [PMID: 29153618 DOI: 10.1016/j.repc.2016.11.015] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2016] [Accepted: 11/09/2016] [Indexed: 11/26/2022] Open
Abstract
INTRODUCTION Aortic stenosis is the most prevalent type of valvular disease in Europe. Surgical aortic valve replacement (SAVR) is the standard therapy, while transcatheter aortic valve implantation (TAVI) is an alternative in patients at unacceptably high surgical risk. Assessment by a heart team is recommended by the guidelines but there is little published evidence on this subject. The purpose of this paper is to describe the experience of a multidisciplinary TAVI program that began in 2008. METHODS The heart team prospectively assessed 473 patients using a standardized approach. A total of 214 patients were selected for TAVI and 80 for SAVR. Demographic, clinical and procedural characteristics and long-term success rates were compared between the groups. RESULTS TAVI patients were older than the SAVR group (median 83 vs. 81 years), and had higher surgical risk scores (median EuroSCORE II 5.3 vs. 3.6% and Society of Thoracic Surgeons score 5.1 vs. 3.1%), as did the patients under medical treatment only. These scores were unable to assess multiple comorbidities. Patients' outcomes were different between the three groups (mortality with SAVR 25% vs. TAVI 37.6% vs. conservative therapy 57.6%, p=0.001). CONCLUSIONS The heart team program was able to select candidates appropriately for TAVI, SAVR and conservative treatment, taking into account the risk of both invasive treatments. The use of a prospective standardized heart team approach is recommended, but requires continuous monitoring to ensure effectiveness in a timely manner.
Collapse
Affiliation(s)
- Cátia Costa
- Serviço de Cardiologia, Hospital Santa Cruz (CHLO), Carnaxide, Portugal; Serviço de Cardiologia, Hospital Santarém, Santarém, Portugal.
| | - Rui Campante Teles
- Serviço de Cardiologia, Hospital Santa Cruz (CHLO), Carnaxide, Portugal; CEDOC, Nova Medical School, Lisboa, Portugal
| | - João Brito
- Serviço de Cardiologia, Hospital Santa Cruz (CHLO), Carnaxide, Portugal
| | - José Pedro Neves
- Serviço de Cirurgia Cardiotorácica, Hospital Santa Cruz (CHLO), Carnaxide, Portugal
| | | | - Miguel Abecassis
- Serviço de Cirurgia Cardiotorácica, Hospital Santa Cruz (CHLO), Carnaxide, Portugal
| | - Regina Ribeiras
- Serviço de Cardiologia, Hospital Santa Cruz (CHLO), Carnaxide, Portugal
| | - João Abecasis
- Serviço de Cardiologia, Hospital Santa Cruz (CHLO), Carnaxide, Portugal; CEDOC, Nova Medical School, Lisboa, Portugal
| | - Tiago Nolasco
- Serviço de Cirurgia Cardiotorácica, Hospital Santa Cruz (CHLO), Carnaxide, Portugal
| | | | - Nélson Vale
- Serviço de Cardiologia, Hospital Santa Cruz (CHLO), Carnaxide, Portugal
| | - António Tralhão
- Serviço de Cardiologia, Hospital Santa Cruz (CHLO), Carnaxide, Portugal
| | - Sérgio Madeira
- Serviço de Cardiologia, Hospital Santa Cruz (CHLO), Carnaxide, Portugal
| | - João Mesquita
- Serviço de Cardiologia, Hospital Santa Cruz (CHLO), Carnaxide, Portugal
| | - Carla Saraiva
- Serviço de Imagiologia, Hospital S. Francisco Xavier (CHLO), Lisboa, Portugal
| | - Rita Calé
- Serviço de Cardiologia, Hospital Santa Cruz (CHLO), Carnaxide, Portugal; Serviço de Cardiologia, Hospital Garcia Orta, Almada, Portugal
| | - Manuel Almeida
- Serviço de Cardiologia, Hospital Santa Cruz (CHLO), Carnaxide, Portugal; CEDOC, Nova Medical School, Lisboa, Portugal
| | - Ana Aleixo
- CEDOC, Nova Medical School, Lisboa, Portugal
| | - Miguel Mendes
- Serviço de Cardiologia, Hospital Santa Cruz (CHLO), Carnaxide, Portugal
| |
Collapse
|
207
|
Costa C, Teles RC, Brito J, Neves JP, Gabriel HM, Abecassis M, Ribeiras R, Abecasis J, Nolasco T, Furstenau MDC, Vale N, Tralhão A, Madeira S, Mesquita J, Saraiva C, Calé R, Almeida M, Aleixo A, Mendes M. Advantages of a prospective multidisciplinary approach in transcatheter aortic valve implantation: Eight years of experience. REVISTA PORTUGUESA DE CARDIOLOGIA (ENGLISH EDITION) 2017. [DOI: 10.1016/j.repce.2017.11.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
208
|
|
209
|
Impact of Frailty on Outcomes in Patients Undergoing Percutaneous Mitral Valve Repair. JACC Cardiovasc Interv 2017; 10:1920-1929. [DOI: 10.1016/j.jcin.2017.07.042] [Citation(s) in RCA: 41] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/21/2017] [Revised: 07/17/2017] [Accepted: 07/26/2017] [Indexed: 11/18/2022]
|
210
|
Antonides CFJ, Mack MJ, Kappetein AP. Approaches to the Role of The Heart Team in Therapeutic Decision Making for Heart Valve Disease. STRUCTURAL HEART 2017. [DOI: 10.1080/24748706.2017.1380377] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Affiliation(s)
- Christiaan F. J. Antonides
- Department of Cardio-Thoracic Surgery, Erasmus University Medical Center Rotterdam, Thoraxcentrum, Rotterdam, The Netherlands
| | - Michael J. Mack
- Baylor Scott and White Healthcare System, Baylor University Medical Center, Baylor Heart and Vascular Hospital, Dallas, Texas, USA
- The Heart Hospital Baylor Plano, Plano, Texas, USA
| | - A. Pieter Kappetein
- Department of Cardio-Thoracic Surgery, Erasmus University Medical Center Rotterdam, Thoraxcentrum, Rotterdam, The Netherlands
| |
Collapse
|
211
|
Grossman Y, Barbash IM, Fefer P, Goldenberg I, Berkovitch A, Regev E, Fink N, Ben-Zekry S, Brodov Y, Kogan A, Guetta V, Raanani E, Segev A. Addition of albumin to Traditional Risk Score Improved Prediction of Mortality in Individuals Undergoing Transcatheter Aortic Valve Replacement. J Am Geriatr Soc 2017; 65:2413-2417. [PMID: 28941287 DOI: 10.1111/jgs.15070] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
OBJECTIVES The ability of the Society of Thoracic Surgeons (STS) and European System for Cardiac Operative Risk Evaluation (EuroSCORE)-2 scores to predict outcomes after transcatheter aortic valve replacement (TAVR) is insufficient. Frailty and serum albumin as a frailty marker were shown to correlate with prognosis after TAVR. We sought to evaluate the additive value of serum albumin to STS and EuroSCORE-2 scores to predict mortality in individuals undergoing TAVR. DESIGN Retrospective analysis. SETTING Tertiary-care hospital prospective registry. PARTICIPANTS Individuals who underwent TAVR (N = 426). MEASUREMENTS We compared survival rates according to median baseline albumin levels (4 g/dL), STS score (4.5%), and EuroSCORE-2 (3.45%). Participants were divided into four groups according to median serum albumin and median STS and EuroSCORE-2 scores (high vs low), and 1-year survival rates were compared. A category-free net reclassification index (NRI) was calculated to compare the ability of a model of STS or EuroSCORE-2 alone to classify mortality risk with and without the addition of baseline serum albumin. RESULTS Participants with low albumin levels had higher mortality (hazard ratio (HR) = 3.03, 95% confidence interval (CI) = 1.66-5.26, P < .001). Participants with low serum albumin and a high STS (HR = 4.55, 95% CI = 2.21-9.38, P < .001) or EuroSCORE-2 (HR = 2.72, 95% CI = 1.48-5.06, P = .001) score had higher mortality. Using NRI analysis, a model that included albumin in addition to STS correctly reclassified 42% of events (NRI = 0.58) and a model that included albumin in addition to EuroSCORE-2 correctly reclassified 44% of events (NRI = 0.64). CONCLUSION Serum albumin, as a marker of frailty, can significantly improve the ability of STS and EuroSCORE-2 scores to predict TAVR-related mortality.
Collapse
Affiliation(s)
- Yoni Grossman
- Heart Center, Chaim Sheba Medical Center, Tel Hashomer, Israel.,Sackler School of Medicine, Tel-Aviv University, Tel Aviv, Israel
| | - Israel M Barbash
- Heart Center, Chaim Sheba Medical Center, Tel Hashomer, Israel.,Sackler School of Medicine, Tel-Aviv University, Tel Aviv, Israel
| | - Paul Fefer
- Heart Center, Chaim Sheba Medical Center, Tel Hashomer, Israel.,Sackler School of Medicine, Tel-Aviv University, Tel Aviv, Israel
| | - Ilan Goldenberg
- Heart Center, Chaim Sheba Medical Center, Tel Hashomer, Israel.,Sackler School of Medicine, Tel-Aviv University, Tel Aviv, Israel
| | - Anat Berkovitch
- Heart Center, Chaim Sheba Medical Center, Tel Hashomer, Israel.,Sackler School of Medicine, Tel-Aviv University, Tel Aviv, Israel
| | - Ehud Regev
- Heart Center, Chaim Sheba Medical Center, Tel Hashomer, Israel.,Sackler School of Medicine, Tel-Aviv University, Tel Aviv, Israel
| | - Noam Fink
- Heart Center, Chaim Sheba Medical Center, Tel Hashomer, Israel.,Sackler School of Medicine, Tel-Aviv University, Tel Aviv, Israel
| | - Sagit Ben-Zekry
- Heart Center, Chaim Sheba Medical Center, Tel Hashomer, Israel.,Sackler School of Medicine, Tel-Aviv University, Tel Aviv, Israel
| | - Yafim Brodov
- Heart Center, Chaim Sheba Medical Center, Tel Hashomer, Israel.,Sackler School of Medicine, Tel-Aviv University, Tel Aviv, Israel
| | - Alexander Kogan
- Heart Center, Chaim Sheba Medical Center, Tel Hashomer, Israel.,Sackler School of Medicine, Tel-Aviv University, Tel Aviv, Israel
| | - Victor Guetta
- Heart Center, Chaim Sheba Medical Center, Tel Hashomer, Israel.,Sackler School of Medicine, Tel-Aviv University, Tel Aviv, Israel
| | - Ehud Raanani
- Heart Center, Chaim Sheba Medical Center, Tel Hashomer, Israel.,Sackler School of Medicine, Tel-Aviv University, Tel Aviv, Israel
| | - Amit Segev
- Heart Center, Chaim Sheba Medical Center, Tel Hashomer, Israel.,Sackler School of Medicine, Tel-Aviv University, Tel Aviv, Israel
| |
Collapse
|
212
|
Maurer MS, Horn E, Reyentovich A, Dickson VV, Pinney S, Goldwater D, Goldstein NE, Jimenez O, Teruya S, Goldsmith J, Helmke S, Yuzefpolskaya M, Reeves GR. Can a Left Ventricular Assist Device in Individuals with Advanced Systolic Heart Failure Improve or Reverse Frailty? J Am Geriatr Soc 2017; 65:2383-2390. [PMID: 28940248 DOI: 10.1111/jgs.15124] [Citation(s) in RCA: 54] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
BACKGROUND/OBJECTIVES Frailty, characterized by low physiological reserves, is strongly associated with vulnerability to adverse outcomes. Features of frailty overlap with those of advanced heart failure, making a distinction between them difficult. We sought to determine whether implantation of a left ventricular assist device (LVAD) would decrease frailty. DESIGN Prospective, cohort study. SETTING Five academic medical centers. PARTICIPANTS Frail individuals (N = 29; mean age 70.6 ± 5.5, 72.4% male). MEASUREMENTS Frailty, defined as having 3 or more of the Fried frailty criteria, was assessed before LVAD implantation and 1, 3, and 6 months after implantation. Other domains assessed included quality of life, using the Kansas City Cardiomyopathy Questionnaire; mood, using the Patient Health Questionnaire; and cognitive function, using the Trail-Making Test Part B. RESULTS After 6 months, three subjects had died, and one had undergone a heart transplant; of 19 subjects with serial frailty measures, the average number of frailty criteria decreased from 3.9 ± 0.9 at baseline to 2.8 ± 1.4 at 6 months (P = .003). Improvements were observed after 3 to 6 months of LVAD support, although 10 (52.6%) participants still had 3 or more Fried criteria, and all subjects had at least one at 6 months. Changes in frailty were associated with improvement in QOL but not with changes in mood or cognition. Higher estimated glomerular filtration rate at baseline was independently associated with a decrease in frailty. CONCLUSION Frailty decreased in approximately half of older adults with advanced heart failure after 6 months of LVAD support. Strategies to enhance frailty reversal in this population are worthy of additional study.
Collapse
Affiliation(s)
- Mathew S Maurer
- Clinical Cardiovascular Research Laboratory for the Elderly, Columbia University Medical Center, Allen Hospital of New York Presbyterian, New York, New York
| | - Evelyn Horn
- Weill Medical College of Cornell University, New York, New York
| | | | | | - Sean Pinney
- Icahn School of Medicine at Mount Sinai, New York, New York
| | | | - Nathan E Goldstein
- Department of Geriatrics, Mount Sinai School of Medicine, New York, New York
| | - Omar Jimenez
- Clinical Cardiovascular Research Laboratory for the Elderly, Columbia University Medical Center, Allen Hospital of New York Presbyterian, New York, New York
| | | | | | - Stephen Helmke
- Clinical Cardiovascular Research Laboratory for the Elderly, Columbia University Medical Center, Allen Hospital of New York Presbyterian, New York, New York
| | - Melana Yuzefpolskaya
- Clinical Cardiovascular Research Laboratory for the Elderly, Columbia University Medical Center, Allen Hospital of New York Presbyterian, New York, New York
| | | |
Collapse
|
213
|
Rodrigues MK, Marques A, Lobo DML, Umeda IIK, Oliveira MF. Pre-Frailty Increases the Risk of Adverse Events in Older Patients Undergoing Cardiovascular Surgery. Arq Bras Cardiol 2017; 109:299-306. [PMID: 28876376 PMCID: PMC5644209 DOI: 10.5935/abc.20170131] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2017] [Accepted: 06/19/2017] [Indexed: 12/20/2022] Open
Abstract
Background Frailty is identified as a major predictor of adverse outcomes in older
surgical patients. However, the outcomes in pre-frail patients after
cardiovascular surgery remain unknown. Objective To investigate the main outcomes (length of stay, mechanical ventilation
time, stroke and in-hospital death) in pre-frail patients in comparison with
no-frail patients after cardiovascular surgery. Methods 221 patients over 65 years old, with established diagnosis of myocardial
infarction or valve disease were enrolled. Patients were evaluated by
Clinical Frailty Score (CFS) before surgery and allocated into 2 groups:
no-frailty (CFS 1~3) vs. pre-frailty (CFS 4) and followed up for main
outcomes. For all analysis, the statistical significance was set at 5% (p
< 0.05). Results No differences were found in anthropometric and demographic data between
groups (p > 0.05). Pre-frail patients showed a longer mechanical
ventilation time (193 ± 37 vs. 29 ± 7 hours; p<0.05) than
no-frail patients; similar results were observed for length of stay at the
intensive care unit (5 ± 1 vs. 3 ± 1 days; p < 0.05) and
total time of hospitalization (12 ± 5 vs. 9 ± 3 days; p <
0.05). In addition, the pre-frail group had a higher number of adverse
events (stroke 8.3% vs. 3.9%; in-hospital death 21.5% vs. 7.8%; p < 0.05)
with an increased risk for development stroke (OR: 2.139, 95% CI:
0.622-7.351, p = 0.001; HR: 2.763, 95%CI: 1.206-6.331, p = 0.0001) and
in-hospital death (OR: 1.809, 95% CI: 1.286-2.546, p = 0.001; HR: 1.830, 95%
CI: 1.476-2.269, p = 0.0001). Moreover, higher number of pre-frail patients
required homecare services than no-frail patients (46.5% vs. 0%; p <
0.05). Conclusion Patients with pre-frailty showed longer mechanical ventilation time and
hospital stay with an increased risk for cardiovascular events compared with
no-frail patients.
Collapse
Affiliation(s)
| | - Artur Marques
- Instituto Dante Pazzanese de Cardiologia, São Paulo, SP, Brazil
| | - Denise M L Lobo
- Faculdade Metropolitana da Grande Fortaleza, Fortaleza, CE, Brazil
| | | | | |
Collapse
|
214
|
Kano S, Yamamoto M, Shimura T, Kagase A, Tsuzuki M, Kodama A, Koyama Y, Kobayashi T, Shibata K, Tada N, Naganuma T, Araki M, Yamanaka F, Shirai S, Mizutani K, Tabata M, Ueno H, Takagi K, Higashimori A, Otsuka T, Watanabe Y, Hayashida K. Gait Speed Can Predict Advanced Clinical Outcomes in Patients Who Undergo Transcatheter Aortic Valve Replacement. Circ Cardiovasc Interv 2017; 10:CIRCINTERVENTIONS.117.005088. [DOI: 10.1161/circinterventions.117.005088] [Citation(s) in RCA: 46] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/03/2017] [Accepted: 07/10/2017] [Indexed: 11/16/2022]
Affiliation(s)
- Seiji Kano
- From the Department of Cardiology, Nagoya Heart Canter, Japan (S.K., M.Y., Y.K., T.K., K.S.); Department of Cardiology, Toyohashi Heart Canter, Japan (M.Y., T.S., A. Kagase, M. Tsuzuki, A. Kodama); Department of Cardiology, Sendai Kosei Hospital, Japan (N.T.); Department of Cardiology, New Tokyo Hospital, Chiba, Japan (T.N.); Department of Cardiology, Saiseikai Yokohama City Eastern Hospital, Japan (M.A.); Department of Cardiology, Syonan Kamakura General Hospital, Japan (F.Y.); Department of
| | - Masanori Yamamoto
- From the Department of Cardiology, Nagoya Heart Canter, Japan (S.K., M.Y., Y.K., T.K., K.S.); Department of Cardiology, Toyohashi Heart Canter, Japan (M.Y., T.S., A. Kagase, M. Tsuzuki, A. Kodama); Department of Cardiology, Sendai Kosei Hospital, Japan (N.T.); Department of Cardiology, New Tokyo Hospital, Chiba, Japan (T.N.); Department of Cardiology, Saiseikai Yokohama City Eastern Hospital, Japan (M.A.); Department of Cardiology, Syonan Kamakura General Hospital, Japan (F.Y.); Department of
| | - Tetsuro Shimura
- From the Department of Cardiology, Nagoya Heart Canter, Japan (S.K., M.Y., Y.K., T.K., K.S.); Department of Cardiology, Toyohashi Heart Canter, Japan (M.Y., T.S., A. Kagase, M. Tsuzuki, A. Kodama); Department of Cardiology, Sendai Kosei Hospital, Japan (N.T.); Department of Cardiology, New Tokyo Hospital, Chiba, Japan (T.N.); Department of Cardiology, Saiseikai Yokohama City Eastern Hospital, Japan (M.A.); Department of Cardiology, Syonan Kamakura General Hospital, Japan (F.Y.); Department of
| | - Ai Kagase
- From the Department of Cardiology, Nagoya Heart Canter, Japan (S.K., M.Y., Y.K., T.K., K.S.); Department of Cardiology, Toyohashi Heart Canter, Japan (M.Y., T.S., A. Kagase, M. Tsuzuki, A. Kodama); Department of Cardiology, Sendai Kosei Hospital, Japan (N.T.); Department of Cardiology, New Tokyo Hospital, Chiba, Japan (T.N.); Department of Cardiology, Saiseikai Yokohama City Eastern Hospital, Japan (M.A.); Department of Cardiology, Syonan Kamakura General Hospital, Japan (F.Y.); Department of
| | - Masanao Tsuzuki
- From the Department of Cardiology, Nagoya Heart Canter, Japan (S.K., M.Y., Y.K., T.K., K.S.); Department of Cardiology, Toyohashi Heart Canter, Japan (M.Y., T.S., A. Kagase, M. Tsuzuki, A. Kodama); Department of Cardiology, Sendai Kosei Hospital, Japan (N.T.); Department of Cardiology, New Tokyo Hospital, Chiba, Japan (T.N.); Department of Cardiology, Saiseikai Yokohama City Eastern Hospital, Japan (M.A.); Department of Cardiology, Syonan Kamakura General Hospital, Japan (F.Y.); Department of
| | - Atsuko Kodama
- From the Department of Cardiology, Nagoya Heart Canter, Japan (S.K., M.Y., Y.K., T.K., K.S.); Department of Cardiology, Toyohashi Heart Canter, Japan (M.Y., T.S., A. Kagase, M. Tsuzuki, A. Kodama); Department of Cardiology, Sendai Kosei Hospital, Japan (N.T.); Department of Cardiology, New Tokyo Hospital, Chiba, Japan (T.N.); Department of Cardiology, Saiseikai Yokohama City Eastern Hospital, Japan (M.A.); Department of Cardiology, Syonan Kamakura General Hospital, Japan (F.Y.); Department of
| | - Yutaka Koyama
- From the Department of Cardiology, Nagoya Heart Canter, Japan (S.K., M.Y., Y.K., T.K., K.S.); Department of Cardiology, Toyohashi Heart Canter, Japan (M.Y., T.S., A. Kagase, M. Tsuzuki, A. Kodama); Department of Cardiology, Sendai Kosei Hospital, Japan (N.T.); Department of Cardiology, New Tokyo Hospital, Chiba, Japan (T.N.); Department of Cardiology, Saiseikai Yokohama City Eastern Hospital, Japan (M.A.); Department of Cardiology, Syonan Kamakura General Hospital, Japan (F.Y.); Department of
| | - Toshihiro Kobayashi
- From the Department of Cardiology, Nagoya Heart Canter, Japan (S.K., M.Y., Y.K., T.K., K.S.); Department of Cardiology, Toyohashi Heart Canter, Japan (M.Y., T.S., A. Kagase, M. Tsuzuki, A. Kodama); Department of Cardiology, Sendai Kosei Hospital, Japan (N.T.); Department of Cardiology, New Tokyo Hospital, Chiba, Japan (T.N.); Department of Cardiology, Saiseikai Yokohama City Eastern Hospital, Japan (M.A.); Department of Cardiology, Syonan Kamakura General Hospital, Japan (F.Y.); Department of
| | - Kenichi Shibata
- From the Department of Cardiology, Nagoya Heart Canter, Japan (S.K., M.Y., Y.K., T.K., K.S.); Department of Cardiology, Toyohashi Heart Canter, Japan (M.Y., T.S., A. Kagase, M. Tsuzuki, A. Kodama); Department of Cardiology, Sendai Kosei Hospital, Japan (N.T.); Department of Cardiology, New Tokyo Hospital, Chiba, Japan (T.N.); Department of Cardiology, Saiseikai Yokohama City Eastern Hospital, Japan (M.A.); Department of Cardiology, Syonan Kamakura General Hospital, Japan (F.Y.); Department of
| | - Norio Tada
- From the Department of Cardiology, Nagoya Heart Canter, Japan (S.K., M.Y., Y.K., T.K., K.S.); Department of Cardiology, Toyohashi Heart Canter, Japan (M.Y., T.S., A. Kagase, M. Tsuzuki, A. Kodama); Department of Cardiology, Sendai Kosei Hospital, Japan (N.T.); Department of Cardiology, New Tokyo Hospital, Chiba, Japan (T.N.); Department of Cardiology, Saiseikai Yokohama City Eastern Hospital, Japan (M.A.); Department of Cardiology, Syonan Kamakura General Hospital, Japan (F.Y.); Department of
| | - Toru Naganuma
- From the Department of Cardiology, Nagoya Heart Canter, Japan (S.K., M.Y., Y.K., T.K., K.S.); Department of Cardiology, Toyohashi Heart Canter, Japan (M.Y., T.S., A. Kagase, M. Tsuzuki, A. Kodama); Department of Cardiology, Sendai Kosei Hospital, Japan (N.T.); Department of Cardiology, New Tokyo Hospital, Chiba, Japan (T.N.); Department of Cardiology, Saiseikai Yokohama City Eastern Hospital, Japan (M.A.); Department of Cardiology, Syonan Kamakura General Hospital, Japan (F.Y.); Department of
| | - Motoharu Araki
- From the Department of Cardiology, Nagoya Heart Canter, Japan (S.K., M.Y., Y.K., T.K., K.S.); Department of Cardiology, Toyohashi Heart Canter, Japan (M.Y., T.S., A. Kagase, M. Tsuzuki, A. Kodama); Department of Cardiology, Sendai Kosei Hospital, Japan (N.T.); Department of Cardiology, New Tokyo Hospital, Chiba, Japan (T.N.); Department of Cardiology, Saiseikai Yokohama City Eastern Hospital, Japan (M.A.); Department of Cardiology, Syonan Kamakura General Hospital, Japan (F.Y.); Department of
| | - Futoshi Yamanaka
- From the Department of Cardiology, Nagoya Heart Canter, Japan (S.K., M.Y., Y.K., T.K., K.S.); Department of Cardiology, Toyohashi Heart Canter, Japan (M.Y., T.S., A. Kagase, M. Tsuzuki, A. Kodama); Department of Cardiology, Sendai Kosei Hospital, Japan (N.T.); Department of Cardiology, New Tokyo Hospital, Chiba, Japan (T.N.); Department of Cardiology, Saiseikai Yokohama City Eastern Hospital, Japan (M.A.); Department of Cardiology, Syonan Kamakura General Hospital, Japan (F.Y.); Department of
| | - Shinichi Shirai
- From the Department of Cardiology, Nagoya Heart Canter, Japan (S.K., M.Y., Y.K., T.K., K.S.); Department of Cardiology, Toyohashi Heart Canter, Japan (M.Y., T.S., A. Kagase, M. Tsuzuki, A. Kodama); Department of Cardiology, Sendai Kosei Hospital, Japan (N.T.); Department of Cardiology, New Tokyo Hospital, Chiba, Japan (T.N.); Department of Cardiology, Saiseikai Yokohama City Eastern Hospital, Japan (M.A.); Department of Cardiology, Syonan Kamakura General Hospital, Japan (F.Y.); Department of
| | - Kazuki Mizutani
- From the Department of Cardiology, Nagoya Heart Canter, Japan (S.K., M.Y., Y.K., T.K., K.S.); Department of Cardiology, Toyohashi Heart Canter, Japan (M.Y., T.S., A. Kagase, M. Tsuzuki, A. Kodama); Department of Cardiology, Sendai Kosei Hospital, Japan (N.T.); Department of Cardiology, New Tokyo Hospital, Chiba, Japan (T.N.); Department of Cardiology, Saiseikai Yokohama City Eastern Hospital, Japan (M.A.); Department of Cardiology, Syonan Kamakura General Hospital, Japan (F.Y.); Department of
| | - Minoru Tabata
- From the Department of Cardiology, Nagoya Heart Canter, Japan (S.K., M.Y., Y.K., T.K., K.S.); Department of Cardiology, Toyohashi Heart Canter, Japan (M.Y., T.S., A. Kagase, M. Tsuzuki, A. Kodama); Department of Cardiology, Sendai Kosei Hospital, Japan (N.T.); Department of Cardiology, New Tokyo Hospital, Chiba, Japan (T.N.); Department of Cardiology, Saiseikai Yokohama City Eastern Hospital, Japan (M.A.); Department of Cardiology, Syonan Kamakura General Hospital, Japan (F.Y.); Department of
| | - Hiroshi Ueno
- From the Department of Cardiology, Nagoya Heart Canter, Japan (S.K., M.Y., Y.K., T.K., K.S.); Department of Cardiology, Toyohashi Heart Canter, Japan (M.Y., T.S., A. Kagase, M. Tsuzuki, A. Kodama); Department of Cardiology, Sendai Kosei Hospital, Japan (N.T.); Department of Cardiology, New Tokyo Hospital, Chiba, Japan (T.N.); Department of Cardiology, Saiseikai Yokohama City Eastern Hospital, Japan (M.A.); Department of Cardiology, Syonan Kamakura General Hospital, Japan (F.Y.); Department of
| | - Kensuke Takagi
- From the Department of Cardiology, Nagoya Heart Canter, Japan (S.K., M.Y., Y.K., T.K., K.S.); Department of Cardiology, Toyohashi Heart Canter, Japan (M.Y., T.S., A. Kagase, M. Tsuzuki, A. Kodama); Department of Cardiology, Sendai Kosei Hospital, Japan (N.T.); Department of Cardiology, New Tokyo Hospital, Chiba, Japan (T.N.); Department of Cardiology, Saiseikai Yokohama City Eastern Hospital, Japan (M.A.); Department of Cardiology, Syonan Kamakura General Hospital, Japan (F.Y.); Department of
| | - Akihiro Higashimori
- From the Department of Cardiology, Nagoya Heart Canter, Japan (S.K., M.Y., Y.K., T.K., K.S.); Department of Cardiology, Toyohashi Heart Canter, Japan (M.Y., T.S., A. Kagase, M. Tsuzuki, A. Kodama); Department of Cardiology, Sendai Kosei Hospital, Japan (N.T.); Department of Cardiology, New Tokyo Hospital, Chiba, Japan (T.N.); Department of Cardiology, Saiseikai Yokohama City Eastern Hospital, Japan (M.A.); Department of Cardiology, Syonan Kamakura General Hospital, Japan (F.Y.); Department of
| | - Toshiaki Otsuka
- From the Department of Cardiology, Nagoya Heart Canter, Japan (S.K., M.Y., Y.K., T.K., K.S.); Department of Cardiology, Toyohashi Heart Canter, Japan (M.Y., T.S., A. Kagase, M. Tsuzuki, A. Kodama); Department of Cardiology, Sendai Kosei Hospital, Japan (N.T.); Department of Cardiology, New Tokyo Hospital, Chiba, Japan (T.N.); Department of Cardiology, Saiseikai Yokohama City Eastern Hospital, Japan (M.A.); Department of Cardiology, Syonan Kamakura General Hospital, Japan (F.Y.); Department of
| | - Yusuke Watanabe
- From the Department of Cardiology, Nagoya Heart Canter, Japan (S.K., M.Y., Y.K., T.K., K.S.); Department of Cardiology, Toyohashi Heart Canter, Japan (M.Y., T.S., A. Kagase, M. Tsuzuki, A. Kodama); Department of Cardiology, Sendai Kosei Hospital, Japan (N.T.); Department of Cardiology, New Tokyo Hospital, Chiba, Japan (T.N.); Department of Cardiology, Saiseikai Yokohama City Eastern Hospital, Japan (M.A.); Department of Cardiology, Syonan Kamakura General Hospital, Japan (F.Y.); Department of
| | - Kentaro Hayashida
- From the Department of Cardiology, Nagoya Heart Canter, Japan (S.K., M.Y., Y.K., T.K., K.S.); Department of Cardiology, Toyohashi Heart Canter, Japan (M.Y., T.S., A. Kagase, M. Tsuzuki, A. Kodama); Department of Cardiology, Sendai Kosei Hospital, Japan (N.T.); Department of Cardiology, New Tokyo Hospital, Chiba, Japan (T.N.); Department of Cardiology, Saiseikai Yokohama City Eastern Hospital, Japan (M.A.); Department of Cardiology, Syonan Kamakura General Hospital, Japan (F.Y.); Department of
| |
Collapse
|
215
|
Shimura T, Yamamoto M, Kano S, Kagase A, Kodama A, Koyama Y, Otsuka T, Kohsaka S, Tada N, Yamanaka F, Naganuma T, Araki M, Shirai S, Mizutani K, Tabata M, Ueno H, Takagi K, Higashimori A, Watanabe Y, Hayashida K. Impact of frailty markers on outcomes after transcatheter aortic valve replacement: insights from a Japanese multicenter registry. Ann Cardiothorac Surg 2017; 6:532-537. [PMID: 29062750 DOI: 10.21037/acs.2017.09.06] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
There are no standardized criteria for measuring patients' frailty. We examined prognosis based on four frailty markers [serum albumin level, grip strength, gait speed, and clinical frailty scale (CFS)] in patients who underwent transcatheter aortic valve replacement (TAVR) between October 2013 and April 2016 and were recorded in the Optimized CathEter vAlvular iNtervention (OCEAN) Japanese multicenter registry. Serum albumin level was assessed by dividing patients into two groups: hypoalbuminemia or non-hypoalbuminemia according to their serum albumin level. Clinical outcomes including all-cause, cardiovascular and non-cardiovascular mortality rates after TAVR were compared. During the follow-up period cumulative all-cause, cardiovascular and non-cardiovascular mortality rates were significantly higher in the hypoalbuminemia group than in the non-hypoalbuminemia group. This result remained unchanged even after a propensity-matched model was used in terms of cumulative all-cause and non-cardiovascular mortality; however, differences in cardiovascular mortality rates were attenuated. To consider the impact of grip strength patients were divided into a low or high peak grip strength group based on classification and regression tree (CART) survival analysis. The clinical outcomes for each sex were compared between the two groups. In both sexes the cumulative 1-year mortality rates were significantly different between the two groups. To investigate gait speed patients were classified into two gait speed groups (low or high gait speed group) based on CART survival analysis. Clinical outcomes were compared between the two groups. The cumulative 1-year mortality rate was significantly different between the two gait speed groups. The effect of CFS on prognosis after TAVR was assessed. Patients were categorized into five groups based on the following CFS scores: CFS1-3, CFS4, CFS5, CFS6, and CFS ≥7. We evaluated the relationship between the CFS score and other indicators of frailty markers. We also assessed the mid-term mortality among the five groups. The CFS score had a significant correlation with other frailty markers. The cumulative 1-year mortality increased with an increasing CFS score. In the Cox regression multivariable analysis, the CFS score was an independent predictive factor of an increased late cumulative mortality risk. In conclusion, the results suggest that serum albumin level, grip strength, gait speed, and CFS score are all useful indicators when considering the optimal indications and risk stratification for TAVR.
Collapse
Affiliation(s)
- Tetsuro Shimura
- Department of Cardiology, Toyohashi Heart Center, Toyohashi, Japan
| | - Masanori Yamamoto
- Department of Cardiology, Toyohashi Heart Center, Toyohashi, Japan.,Department of Cardiology, Nagoya Heart Center, Nagoya, Japan
| | - Seiji Kano
- Department of Cardiology, Nagoya Heart Center, Nagoya, Japan
| | - Ai Kagase
- Department of Cardiology, Toyohashi Heart Center, Toyohashi, Japan
| | - Atsuko Kodama
- Department of Cardiology, Toyohashi Heart Center, Toyohashi, Japan
| | - Yutaka Koyama
- Department of Cardiology, Nagoya Heart Center, Nagoya, Japan
| | - Toshiaki Otsuka
- Department of Hygiene and Public Health, Nippon Medical School, Tokyo, Japan.,Center for Clinical Research, Nippon Medical School Hospital, Tokyo, Japan
| | - Shun Kohsaka
- Department of Cardiology, Keio University School of Medicine, Tokyo, Japan
| | - Norio Tada
- Department of Cardiology, Sendai Kousei Hospital, Sendai, Japan
| | - Futoshi Yamanaka
- Department of Cardiology, Shonan Kamakura General Hospital, Kamakura, Japan
| | - Toru Naganuma
- Department of Cardiology, New Tokyo Hospital, Chiba, Japan
| | - Motoharu Araki
- Department of Cardiology, Saiseikai Yokohama City Eastern Hospital, Yokohama, Japan
| | - Shinichi Shirai
- Department of Cardiology, Kokura Memorial Hospital, Kokura, Japan
| | - Kazuki Mizutani
- Department of Cardiology, Osaka City University Hospital, Osaka, Japan
| | - Minoru Tabata
- Department of Cardiology, Tokyo Bay Urayasu Ichikawa Medical Center, Urayasu, Japan
| | - Hiroshi Ueno
- Department of Cardiology, Toyama University Hospital, Toyama, Japan
| | - Kensuke Takagi
- Department of Cardiology, Ogaki Municipal Hospital, Ogaki, Japan
| | | | - Yusuke Watanabe
- Department of Cardiology, Teikyo University School of Medicine, Tokyo, Japan
| | - Kentaro Hayashida
- Department of Cardiology, Keio University School of Medicine, Tokyo, Japan
| |
Collapse
|
216
|
Dharmarajan K. What Can Geriatrics Teach Cardiology? CURRENT CARDIOVASCULAR RISK REPORTS 2017; 10. [PMID: 28729895 DOI: 10.1007/s12170-016-0516-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Affiliation(s)
- Kumar Dharmarajan
- Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, Center for Outcomes Research and Evaluation, Yale-New Haven Hospital, 1 Church Street, Suite 200, New Haven, CT, 06510, USA
| |
Collapse
|
217
|
Sacha J, Sacha M, Soboń J, Borysiuk Z, Feusette P. Is It Time to Begin a Public Campaign Concerning Frailty and Pre-frailty? A Review Article. Front Physiol 2017; 8:484. [PMID: 28744225 PMCID: PMC5504234 DOI: 10.3389/fphys.2017.00484] [Citation(s) in RCA: 71] [Impact Index Per Article: 8.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2016] [Accepted: 06/23/2017] [Indexed: 01/06/2023] Open
Abstract
Frailty is a state that encompasses losses in physical, psychological or social domains. Therefore, frail people demonstrate a reduced potential to manage external stressors and to respond to life incidents. Consequently, such persons are prone to various adverse consequences such as falls, cognitive decline, infections, hospitalization, disability, institutionalization, and death. Pre-frailty is a condition predisposing and usually preceding the frailty state. Early detection of frailty (i.e., pre-frailty) may present an opportunity to introduce effective management to improve outcomes. Exercise training appears to be the basis of such management in addition to periodic monitoring of food intake and body weight. However, various nutritional supplements and other probable interventions, such as treatment with vitamin D or androgen, require further investigation. Notably, many societies are not conscious of frailty as a health problem. In fact, people generally do not realize that they can change this unfavorable trajectory to senility. As populations age, it is reasonable to begin treating frailty similarly to other population-affecting disorders (e.g., obesity, diabetes or cardiovascular diseases) and implement appropriate preventative measures. Social campaigns should inform societies about age-related frailty and pre-frailty and suggest appropriate lifestyles to avoid or delay these conditions. In this article, we review current information concerning therapeutic interventions in frailty and pre-frailty and discuss whether a greater public awareness of such conditions and some preventative and therapeutic measures may decrease their prevalence.
Collapse
Affiliation(s)
- Jerzy Sacha
- Faculty of Physical Education and Physiotherapy, Opole University of TechnologyOpole, Poland
- Department of Cardiology, University Hospital of the University of OpoleOpole, Poland
| | | | - Jacek Soboń
- Faculty of Physical Education and Physiotherapy, Opole University of TechnologyOpole, Poland
| | - Zbigniew Borysiuk
- Faculty of Physical Education and Physiotherapy, Opole University of TechnologyOpole, Poland
| | - Piotr Feusette
- Department of Cardiology, University Hospital of the University of OpoleOpole, Poland
| |
Collapse
|
218
|
Witberg G, Regev E, Chen S, Assali A, Barbash IM, Planer D, Vaknin-Assa H, Guetta V, Vukasinovic V, Orvin K, Danenberg HD, Segev A, Kornowski R. The Prognostic Effects of Coronary Disease Severity and Completeness of Revascularization on Mortality in Patients Undergoing Transcatheter Aortic Valve Replacement. JACC Cardiovasc Interv 2017; 10:1428-1435. [DOI: 10.1016/j.jcin.2017.04.035] [Citation(s) in RCA: 90] [Impact Index Per Article: 11.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/13/2017] [Revised: 04/17/2017] [Accepted: 04/19/2017] [Indexed: 11/27/2022]
|
219
|
Conte JV, Hermiller J, Resar JR, Deeb GM, Gleason TG, Adams DH, Popma JJ, Yakubov SJ, Watson D, Guo J, Zorn GL, Reardon MJ. Complications After Self-expanding Transcatheter or Surgical Aortic Valve Replacement. Semin Thorac Cardiovasc Surg 2017; 29:321-330. [PMID: 29195573 DOI: 10.1053/j.semtcvs.2017.06.001] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/01/2017] [Indexed: 11/11/2022]
Abstract
Procedural complications following transcatheter aortic valve replacement (TAVR) or surgical aortic valve replacement (SAVR) are usually reported as retrospective analyses. We report the first comparison of complications following SAVR or self-expanding TAVR from a prospectively randomized study of high-risk SAVR patients. Three hundred ninety-five TAVR and 402 SAVR patients were prospectively enrolled and randomized 1:1 to TAVR with a CoreValve bioprosthesis or a surgical bioprosthetic valve. The rates of major procedural and vascular complications occurring (periprocedurally (0-3 days) and early (4-30 days)) were compared for TAVR vs SAVR patients. All-cause mortality, stroke, myocardial infarction, and major infection were similar in both periods post procedure. Within 0-3 days, the major vascular complication rate was significantly higher with TAVR (P = 0.003). Life-threatening or disabling bleeding (P < 0.001), encephalopathy (P = 0.02), atrial fibrillation (P < 0.001), and acute kidney injury (P < 0.001) were significantly higher with SAVR. Non-iliofemoral TAVR approaches had a higher incidence of major or life-threatening or disabling bleeding at 0-3days (P < 0.05). Procedural complications unique to TAVR included coronary occlusion 0.5% (2) and TAVR pop outs 2.8% (11) with no valve embolizations. Pop outs were similar between iliofemoral 2.8% (9/324) and non-iliofemoral approaches 3.0% (2/66). Procedural complications unique to SAVR included aortic dissection 0.8% (3/357) and injury to other heart structures 2.0% (7/357). The procedural complication profiles of TAVR and SAVR are unique. Intraoperative deaths were seen in TAVR only. Mortality at 3 and 30 days was similar. The higher incidence of some complications likely reflects the greater invasiveness of SAVR in this aged high-risk population.
Collapse
Affiliation(s)
- John V Conte
- Departments of Surgery and Medicine, Johns Hopkins University, Baltimore, Maryland.
| | - James Hermiller
- St. Vincent's Heart Center of Indiana, Indianapolis, Indiana
| | - Jon R Resar
- Departments of Surgery and Medicine, Johns Hopkins University, Baltimore, Maryland
| | - G Michael Deeb
- Department of Surgery, University of Michigan, Ann Arbor, Michigan
| | - Thomas G Gleason
- Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
| | - David H Adams
- Department of Cardiovascular Surgery, Mount Sinai Medical Center, New York, New York
| | - Jeffrey J Popma
- Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts
| | | | | | - Jia Guo
- Medtronic, Minneapolis, Minnesota
| | - George L Zorn
- Cardiovascular Research Institute, University of Kansas Hospital, Kansas City, Kansas
| | - Michael J Reardon
- Department of Surgery, Houston Methodist DeBakey Heart and Vascular Center, Houston, Texas
| |
Collapse
|
220
|
Sanchis J, Ruiz V, Bonanad C, Valero E, Ruescas-Nicolau MA, Ezzatvar Y, Sastre C, García-Blas S, Mollar A, Bertomeu-González V, Miñana G, Núñez J. Prognostic Value of Geriatric Conditions Beyond Age After Acute Coronary Syndrome. Mayo Clin Proc 2017; 92:934-939. [PMID: 28389067 DOI: 10.1016/j.mayocp.2017.01.018] [Citation(s) in RCA: 41] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/07/2016] [Revised: 01/20/2017] [Accepted: 01/27/2017] [Indexed: 01/17/2023]
Abstract
The aim of the present study was to investigate the prognostic value of geriatric conditions beyond age after acute coronary syndrome. This was a prospective cohort design including 342 patients (from October 1, 2010, to February 1, 2012) hospitalized for acute coronary syndrome, older than 65 years, in whom 5 geriatric conditions were evaluated at discharge: frailty (Fried and Green scales), comorbidity (Charlson and simple comorbidity indexes), cognitive impairment (Pfeiffer test), physical disability (Barthel index), and instrumental disability (Lawton-Brody scale). The primary end point was all-cause mortality. The median follow-up for the entire population was 4.7 years (range, 3-2178 days). A total of 156 patients (46%) died. Among the geriatric conditions, frailty (Green score, per point; hazard ratio, 1.11; 95% CI, 1.02-1.20; P=.01) and comorbidity (Charlson index, per point; hazard ratio, 1.18; 95% CI, 1.0-1.40; P=.05) were the independent predictors. The introduction of age in a basic model using well-established prognostic clinical variables resulted in an increase in discrimination accuracy (C-statistic=.716-.744; P=.05), though the addition of frailty and comorbidity provided a nonsignificant further increase (C-statistic=.759; P=.36). Likewise, the addition of age to the clinical model led to a significant risk reclassification (continuous net reclassification improvement, 0.46; 95% CI, 0.21-0.67; and integrated discrimination improvement, 0.04; 95% CI, 0.01-0.09). However, the addition of frailty and comorbidity provided a further significant risk reclassification in comparison to the clinical model with age (continuous net reclassification improvement, 0.40; 95% CI, 0.16-0.65; and integrated discrimination improvement, 0.04; 95% CI, 0.01-0.10). In conclusion, frailty and comorbidity are mortality predictors that significantly reclassify risk beyond age after acute coronary syndrome.
Collapse
Affiliation(s)
- Juan Sanchis
- Cardiology Department, University Clinic Hospital, INCLIVA, Valencia, Spain; CIBER-CV, University of Valencia, Valencia, Spain.
| | - Vicente Ruiz
- CIBER-CV, University of Valencia, Valencia, Spain; Nursing School, University of Valencia, Valencia, Spain
| | - Clara Bonanad
- Cardiology Department, University Clinic Hospital, INCLIVA, Valencia, Spain; CIBER-CV, University of Valencia, Valencia, Spain
| | - Ernesto Valero
- Cardiology Department, University Clinic Hospital, INCLIVA, Valencia, Spain; CIBER-CV, University of Valencia, Valencia, Spain
| | | | - Yasmin Ezzatvar
- Cardiology Department, University Clinic Hospital, INCLIVA, Valencia, Spain
| | - Clara Sastre
- Cardiology Department, University Clinic Hospital, INCLIVA, Valencia, Spain
| | - Sergio García-Blas
- Cardiology Department, University Clinic Hospital, INCLIVA, Valencia, Spain; CIBER-CV, University of Valencia, Valencia, Spain
| | - Anna Mollar
- Cardiology Department, University Clinic Hospital, INCLIVA, Valencia, Spain
| | | | - Gema Miñana
- Cardiology Department, University Clinic Hospital, INCLIVA, Valencia, Spain; CIBER-CV, University of Valencia, Valencia, Spain; Department of Medicine, University of Valencia, Valencia, Spain
| | - Julio Núñez
- Cardiology Department, University Clinic Hospital, INCLIVA, Valencia, Spain; CIBER-CV, University of Valencia, Valencia, Spain; Department of Medicine, University of Valencia, Valencia, Spain
| |
Collapse
|
221
|
Using a multidimensional prognostic index (MPI) based on comprehensive geriatric assessment (CGA) to predict mortality in elderly undergoing transcatheter aortic valve implantation. Int J Cardiol 2017; 236:381-386. [DOI: 10.1016/j.ijcard.2017.02.048] [Citation(s) in RCA: 36] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/08/2016] [Revised: 01/11/2017] [Accepted: 02/13/2017] [Indexed: 11/20/2022]
|
222
|
Corrêa WO, Batista VGR, Cavalcante Júnior EF, Fernandes MP, Fortes R, Ruiz GZL, Machado CJ, Pastore Neto M. Preditores de mortalidade em pacientes com fratura de pelve por trauma contuso. Rev Col Bras Cir 2017; 44:222-230. [DOI: 10.1590/0100-69912017003001] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2017] [Accepted: 02/12/2017] [Indexed: 11/22/2022] Open
Abstract
RESUMO Objetivo: analisar a associação de mortalidade com variáveis sociodemográficas, clínicas, lesões e complicações em pacientes com trauma de pelve decorrente de trauma contuso. Métodos: estudo retrospectivo e observacional com dados de registro de trauma obtidos durante cinco anos. O óbito foi a variável de estratificação das análises. Para verificar se as variáveis de interesse tinham associação com o óbito, foi realizado o teste t de Student e teste do Qui-quadrado (ou Fisher) e Wilcoxon-Mann Whitney. Os fatores independentemente associados ao óbito foram analisados por modelo logístico binomial, e com base nos testes de Wald e por Critérios de Informação de Akaike (AIC) e Bayesiano de Schwarz (BIC). Resultados: dos 28 pacientes com fratura de pelve por trauma contuso, 23 (82,1%) eram homens; 16 (57,1%) com média de idade de 38,8 anos (desvio padrão 17,3). Houve 98 lesões ou fraturas nos 28 pacientes. Quanto à gravidade, sete pacientes tiveram Injury Severity Score superior a 24 (25%). O tempo de internação hospitalar médio foi 26,8 dias (DP=22,4). Quinze pacientes (53,6%) tiveram internação em UTI. A incidência de óbito foi de 21,4%. A análise mostrou que idade igual ou maior do que 50 anos e presença de coagulopatia foram fatores independentemente associados ao óbito. Conclusão: as fraturas de pelve podem ter mortalidade elevada. Neste estudo a mortalidade foi superior ao que é descrito na literatura. A idade acima de 50 anos e a coagulopatia se revelaram fatores de risco nessa população.
Collapse
|
223
|
Shimura T, Yamamoto M, Kano S, Kagase A, Kodama A, Koyama Y, Tsuchikane E, Suzuki T, Otsuka T, Kohsaka S, Tada N, Yamanaka F, Naganuma T, Araki M, Shirai S, Watanabe Y, Hayashida K, Yashima F, Inohara T, Kakefuda Y, Arai T, Yanagisawa R, Tanaka M, Kawakami T, Maekawa Y, Takashi K, Yoshitake A, Iida Y, Yamazaki M, Shimizu H, Yamada Y, Jinzaki M, Tsuruta H, Itabashi Y, Murata M, Kawakami M, Fukui S, Sano M, Fukuda K, Hosoba S, Sato H, Teramoto T, Kimura M, Sago M, Tsunaki T, Watarai S, Tsuzuki M, Irokawa K, Shimizu K, Kobayashi T, Okawa Y, Miyasaka M, Enta Y, Shishido K, Ochiai T, Yamabe T, Noguchi K, Saito S, Kawamoto H, Onishi H, Yabushita H, Mitomo S, Nakamura S, Yamawaki M, Akatsu Y, Honda Y, Takama T, Isotani A, Hayashi M, Kamioka N, Miura M, Morinaga T, Kawaguchi T, Yano M, Hanyu M, Arai Y, Tsubota H, Kudo M, Kuroda Y, Kataoka A, Hioki H, Nara Y, Kawashima H, Nagura F, Nakashima M, Sasaki K, Nishikawa J, Shimokawa T, Harada T, Kozuma K. Impact of the Clinical Frailty Scale on Outcomes After Transcatheter Aortic Valve Replacement. Circulation 2017; 135:2013-2024. [DOI: 10.1161/circulationaha.116.025630] [Citation(s) in RCA: 165] [Impact Index Per Article: 20.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/22/2016] [Accepted: 03/01/2017] [Indexed: 12/14/2022]
Abstract
Background:
The semiquantitative Clinical Frailty Scale (CFS) is a simple tool to assess patients’ frailty and has been shown to correlate with mortality in elderly patients even when evaluated by nongeriatricians. The aim of the current study was to determine the prognostic value of CFS in patients who underwent transcatheter aortic valve replacement.
Methods:
We utilized the OCEAN (Optimized Catheter Valvular Intervention) Japanese multicenter registry to review data of 1215 patients who underwent transcatheter aortic valve replacement. Patients were categorized into 5 groups based on the CFS stages: CFS 1-3, CFS 4, CFS 5, CFS 6, and CFS ≥7. We subsequently evaluated the relationship between CFS grading and other indicators of frailty, including body mass index, serum albumin, gait speed, and mean hand grip. We also assessed differences in baseline characteristics, procedural outcomes, and early and midterm mortality among the 5 groups.
Results:
Patient distribution into the 5 CFS groups was as follows: 38.0% (CFS 1-3), 32.9% (CFS4), 15.1% (CFS 5), 10.0% (CFS 6), and 4.0% (CFS ≥7). The CFS grade showed significant correlation with body mass index (Spearman’s ρ=−0.077,
P
=0.007), albumin (ρ=−0.22,
P
<0.001), gait speed (ρ=−0.28,
P
<0.001), and grip strength (ρ=−0.26,
P
<0.001). Cumulative 1-year mortality increased with increasing CFS stage (7.2%, 8.6%. 15.7%, 16.9%, 44.1%,
P
<0.001). In a Cox regression multivariate analysis, the CFS (per 1 category increase) was an independent predictive factor of increased late cumulative mortality risk (hazard ratio, 1.28; 95% confidence interval, 1.10–1.49;
P
<0.001).
Conclusions:
In addition to reflecting the degree of frailty, the CFS was a useful marker for predicting late mortality in an elderly transcatheter aortic valve replacement cohort.
Collapse
Affiliation(s)
- Tetsuro Shimura
- From Department of Cardiology, Toyohashi Heart Center, Toyohashi, Japan (T. Shimura, M.Y., A. Kagase, A. Kodama, E.T., T. Suzuki); Department of Cardiology, Nagoya Heart Center, Japan (M.Y., S. Kano, Y.K.); Department of Hygiene and Public Health, Nippon Medical School, Tokyo, Japan (T.O.); Center for Clinical Research, Nippon Medical School Hospital, Tokyo, Japan (T.O.); Department of Cardiology, Keio University School of Medicine, Tokyo, Japan (S. Kohsaka, K.H.); Department of Cardiology, Sendai
| | - Masanori Yamamoto
- From Department of Cardiology, Toyohashi Heart Center, Toyohashi, Japan (T. Shimura, M.Y., A. Kagase, A. Kodama, E.T., T. Suzuki); Department of Cardiology, Nagoya Heart Center, Japan (M.Y., S. Kano, Y.K.); Department of Hygiene and Public Health, Nippon Medical School, Tokyo, Japan (T.O.); Center for Clinical Research, Nippon Medical School Hospital, Tokyo, Japan (T.O.); Department of Cardiology, Keio University School of Medicine, Tokyo, Japan (S. Kohsaka, K.H.); Department of Cardiology, Sendai
| | - Seiji Kano
- From Department of Cardiology, Toyohashi Heart Center, Toyohashi, Japan (T. Shimura, M.Y., A. Kagase, A. Kodama, E.T., T. Suzuki); Department of Cardiology, Nagoya Heart Center, Japan (M.Y., S. Kano, Y.K.); Department of Hygiene and Public Health, Nippon Medical School, Tokyo, Japan (T.O.); Center for Clinical Research, Nippon Medical School Hospital, Tokyo, Japan (T.O.); Department of Cardiology, Keio University School of Medicine, Tokyo, Japan (S. Kohsaka, K.H.); Department of Cardiology, Sendai
| | - Ai Kagase
- From Department of Cardiology, Toyohashi Heart Center, Toyohashi, Japan (T. Shimura, M.Y., A. Kagase, A. Kodama, E.T., T. Suzuki); Department of Cardiology, Nagoya Heart Center, Japan (M.Y., S. Kano, Y.K.); Department of Hygiene and Public Health, Nippon Medical School, Tokyo, Japan (T.O.); Center for Clinical Research, Nippon Medical School Hospital, Tokyo, Japan (T.O.); Department of Cardiology, Keio University School of Medicine, Tokyo, Japan (S. Kohsaka, K.H.); Department of Cardiology, Sendai
| | - Atsuko Kodama
- From Department of Cardiology, Toyohashi Heart Center, Toyohashi, Japan (T. Shimura, M.Y., A. Kagase, A. Kodama, E.T., T. Suzuki); Department of Cardiology, Nagoya Heart Center, Japan (M.Y., S. Kano, Y.K.); Department of Hygiene and Public Health, Nippon Medical School, Tokyo, Japan (T.O.); Center for Clinical Research, Nippon Medical School Hospital, Tokyo, Japan (T.O.); Department of Cardiology, Keio University School of Medicine, Tokyo, Japan (S. Kohsaka, K.H.); Department of Cardiology, Sendai
| | - Yutaka Koyama
- From Department of Cardiology, Toyohashi Heart Center, Toyohashi, Japan (T. Shimura, M.Y., A. Kagase, A. Kodama, E.T., T. Suzuki); Department of Cardiology, Nagoya Heart Center, Japan (M.Y., S. Kano, Y.K.); Department of Hygiene and Public Health, Nippon Medical School, Tokyo, Japan (T.O.); Center for Clinical Research, Nippon Medical School Hospital, Tokyo, Japan (T.O.); Department of Cardiology, Keio University School of Medicine, Tokyo, Japan (S. Kohsaka, K.H.); Department of Cardiology, Sendai
| | - Etsuo Tsuchikane
- From Department of Cardiology, Toyohashi Heart Center, Toyohashi, Japan (T. Shimura, M.Y., A. Kagase, A. Kodama, E.T., T. Suzuki); Department of Cardiology, Nagoya Heart Center, Japan (M.Y., S. Kano, Y.K.); Department of Hygiene and Public Health, Nippon Medical School, Tokyo, Japan (T.O.); Center for Clinical Research, Nippon Medical School Hospital, Tokyo, Japan (T.O.); Department of Cardiology, Keio University School of Medicine, Tokyo, Japan (S. Kohsaka, K.H.); Department of Cardiology, Sendai
| | - Takahiko Suzuki
- From Department of Cardiology, Toyohashi Heart Center, Toyohashi, Japan (T. Shimura, M.Y., A. Kagase, A. Kodama, E.T., T. Suzuki); Department of Cardiology, Nagoya Heart Center, Japan (M.Y., S. Kano, Y.K.); Department of Hygiene and Public Health, Nippon Medical School, Tokyo, Japan (T.O.); Center for Clinical Research, Nippon Medical School Hospital, Tokyo, Japan (T.O.); Department of Cardiology, Keio University School of Medicine, Tokyo, Japan (S. Kohsaka, K.H.); Department of Cardiology, Sendai
| | - Toshiaki Otsuka
- From Department of Cardiology, Toyohashi Heart Center, Toyohashi, Japan (T. Shimura, M.Y., A. Kagase, A. Kodama, E.T., T. Suzuki); Department of Cardiology, Nagoya Heart Center, Japan (M.Y., S. Kano, Y.K.); Department of Hygiene and Public Health, Nippon Medical School, Tokyo, Japan (T.O.); Center for Clinical Research, Nippon Medical School Hospital, Tokyo, Japan (T.O.); Department of Cardiology, Keio University School of Medicine, Tokyo, Japan (S. Kohsaka, K.H.); Department of Cardiology, Sendai
| | - Shun Kohsaka
- From Department of Cardiology, Toyohashi Heart Center, Toyohashi, Japan (T. Shimura, M.Y., A. Kagase, A. Kodama, E.T., T. Suzuki); Department of Cardiology, Nagoya Heart Center, Japan (M.Y., S. Kano, Y.K.); Department of Hygiene and Public Health, Nippon Medical School, Tokyo, Japan (T.O.); Center for Clinical Research, Nippon Medical School Hospital, Tokyo, Japan (T.O.); Department of Cardiology, Keio University School of Medicine, Tokyo, Japan (S. Kohsaka, K.H.); Department of Cardiology, Sendai
| | - Norio Tada
- From Department of Cardiology, Toyohashi Heart Center, Toyohashi, Japan (T. Shimura, M.Y., A. Kagase, A. Kodama, E.T., T. Suzuki); Department of Cardiology, Nagoya Heart Center, Japan (M.Y., S. Kano, Y.K.); Department of Hygiene and Public Health, Nippon Medical School, Tokyo, Japan (T.O.); Center for Clinical Research, Nippon Medical School Hospital, Tokyo, Japan (T.O.); Department of Cardiology, Keio University School of Medicine, Tokyo, Japan (S. Kohsaka, K.H.); Department of Cardiology, Sendai
| | - Futoshi Yamanaka
- From Department of Cardiology, Toyohashi Heart Center, Toyohashi, Japan (T. Shimura, M.Y., A. Kagase, A. Kodama, E.T., T. Suzuki); Department of Cardiology, Nagoya Heart Center, Japan (M.Y., S. Kano, Y.K.); Department of Hygiene and Public Health, Nippon Medical School, Tokyo, Japan (T.O.); Center for Clinical Research, Nippon Medical School Hospital, Tokyo, Japan (T.O.); Department of Cardiology, Keio University School of Medicine, Tokyo, Japan (S. Kohsaka, K.H.); Department of Cardiology, Sendai
| | - Toru Naganuma
- From Department of Cardiology, Toyohashi Heart Center, Toyohashi, Japan (T. Shimura, M.Y., A. Kagase, A. Kodama, E.T., T. Suzuki); Department of Cardiology, Nagoya Heart Center, Japan (M.Y., S. Kano, Y.K.); Department of Hygiene and Public Health, Nippon Medical School, Tokyo, Japan (T.O.); Center for Clinical Research, Nippon Medical School Hospital, Tokyo, Japan (T.O.); Department of Cardiology, Keio University School of Medicine, Tokyo, Japan (S. Kohsaka, K.H.); Department of Cardiology, Sendai
| | - Motoharu Araki
- From Department of Cardiology, Toyohashi Heart Center, Toyohashi, Japan (T. Shimura, M.Y., A. Kagase, A. Kodama, E.T., T. Suzuki); Department of Cardiology, Nagoya Heart Center, Japan (M.Y., S. Kano, Y.K.); Department of Hygiene and Public Health, Nippon Medical School, Tokyo, Japan (T.O.); Center for Clinical Research, Nippon Medical School Hospital, Tokyo, Japan (T.O.); Department of Cardiology, Keio University School of Medicine, Tokyo, Japan (S. Kohsaka, K.H.); Department of Cardiology, Sendai
| | - Shinichi Shirai
- From Department of Cardiology, Toyohashi Heart Center, Toyohashi, Japan (T. Shimura, M.Y., A. Kagase, A. Kodama, E.T., T. Suzuki); Department of Cardiology, Nagoya Heart Center, Japan (M.Y., S. Kano, Y.K.); Department of Hygiene and Public Health, Nippon Medical School, Tokyo, Japan (T.O.); Center for Clinical Research, Nippon Medical School Hospital, Tokyo, Japan (T.O.); Department of Cardiology, Keio University School of Medicine, Tokyo, Japan (S. Kohsaka, K.H.); Department of Cardiology, Sendai
| | - Yusuke Watanabe
- From Department of Cardiology, Toyohashi Heart Center, Toyohashi, Japan (T. Shimura, M.Y., A. Kagase, A. Kodama, E.T., T. Suzuki); Department of Cardiology, Nagoya Heart Center, Japan (M.Y., S. Kano, Y.K.); Department of Hygiene and Public Health, Nippon Medical School, Tokyo, Japan (T.O.); Center for Clinical Research, Nippon Medical School Hospital, Tokyo, Japan (T.O.); Department of Cardiology, Keio University School of Medicine, Tokyo, Japan (S. Kohsaka, K.H.); Department of Cardiology, Sendai
| | - Kentaro Hayashida
- From Department of Cardiology, Toyohashi Heart Center, Toyohashi, Japan (T. Shimura, M.Y., A. Kagase, A. Kodama, E.T., T. Suzuki); Department of Cardiology, Nagoya Heart Center, Japan (M.Y., S. Kano, Y.K.); Department of Hygiene and Public Health, Nippon Medical School, Tokyo, Japan (T.O.); Center for Clinical Research, Nippon Medical School Hospital, Tokyo, Japan (T.O.); Department of Cardiology, Keio University School of Medicine, Tokyo, Japan (S. Kohsaka, K.H.); Department of Cardiology, Sendai
| | | | - Taku Inohara
- Keio University School of Medicine, Tokyo, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | - Shogo Fukui
- Keio University School of Medicine, Tokyo, Japan
| | - Motoaki Sano
- Keio University School of Medicine, Tokyo, Japan
| | | | - Soh Hosoba
- Toyohashi Heart Center, Toyohashi, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | - Yui Akatsu
- Saiseikai Yokohama City Eastern Hospital, Yokohama, Japan
| | - Yosuke Honda
- Saiseikai Yokohama City Eastern Hospital, Yokohama, Japan
| | - Takuro Takama
- Saiseikai Yokohama City Eastern Hospital, Yokohama, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | - Yugo Nara
- Teikyo University School of Medicine, Tokyo, Japan
| | | | | | | | | | | | | | | | - Ken Kozuma
- Teikyo University School of Medicine, Tokyo, Japan
| |
Collapse
|
224
|
Kobayashi Y, Kim JB, Moneghetti KJ, Kobayashi Y, Zhang R, Brenner DA, O'Malley R, Schnittger I, Fischbein M, Miller DC, Yeung AC, Liang D, Haddad F, Fearon WF. Dynamic changes in aortic impedance after transcatheter aortic valve replacement and its impact on exploratory outcome. Int J Cardiovasc Imaging 2017; 33:1693-1701. [PMID: 28516313 DOI: 10.1007/s10554-017-1155-6] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/09/2017] [Accepted: 05/02/2017] [Indexed: 11/25/2022]
Abstract
Valvulo-arterial impedance (Zva) has been shown to predict worse outcome in medically managed aortic stenosis (AS) patients. We aimed to investigate the association between Zva and left ventricular (LV) adaptation and to explore the predictive value of Zva for cardiac functional recovery and outcome after transcatheter aortic valve replacement (TAVR). We prospectively enrolled 128 patients with AS who underwent TAVR. Zva was calculated as: (systolic blood pressure + mean transaortic gradient)/stroke volume index). Echocardiographic assessment occurred at baseline, 1-month and 1-year after TAVR. The primary endpoints were to investigate associations between Zva and global longitudinal strain (GLS) at baseline as well as GLS change after TAVR. The secondary was to compare all-cause mortality after TAVR between patients with pre-defined Zva (=5 mmHg m2/ml), stroke volume index (=35 ml/m2), and GLS (=-15%) cutoffs. The mean GLS was reduced (-13.0 ± 3.2%). The mean Zva was 5.2 ± 1.6 mmHg*m2/ml with 55% of values ≥5.0 mmHg*m2/ml, considered to be abnormally high. Higher Zva correlated with worse GLS (r = -0.33, p < 0.001). After TAVR, Zva decreased significantly (5.1 ± 1.6 vs. 4.5 ± 1.6 mmHg*m2/ml, p = 0.001). A reduction of Zva at 1-month was associated with GLS improvement at 1-month (r = -0.31, p = 0.001) and at 1-year (r = -0.36 and p = 0.001). By Kaplan-Meier analysis, patients with higher Zva at baseline had higher mortality (Log-rank p = 0.046), while stroke volume index and GLS did not differentiate outcome (Log-rank p = 0.09 and 0.25, respectively). As a conclusion, Zva is correlated with GLS in AS as well as GLS improvement after TAVR. Furthermore, a high baseline Zva may have an additional impact to traditional parameters on predicting worse mortality after TAVR.
Collapse
Affiliation(s)
- Yukari Kobayashi
- Division of Cardiovascular Medicine, Stanford University School of Medicine, 300 Pasteur Drive Room H2103, Stanford, CA, 94305, USA.,Stanford Cardiovascular Institute, Stanford, CA, USA
| | - Juyong B Kim
- Division of Cardiovascular Medicine, Stanford University School of Medicine, 300 Pasteur Drive Room H2103, Stanford, CA, 94305, USA.,Stanford Cardiovascular Institute, Stanford, CA, USA
| | - Kegan J Moneghetti
- Division of Cardiovascular Medicine, Stanford University School of Medicine, 300 Pasteur Drive Room H2103, Stanford, CA, 94305, USA.,Stanford Cardiovascular Institute, Stanford, CA, USA
| | - Yuhei Kobayashi
- Division of Cardiovascular Medicine, Stanford University School of Medicine, 300 Pasteur Drive Room H2103, Stanford, CA, 94305, USA.,Stanford Cardiovascular Institute, Stanford, CA, USA
| | - Ran Zhang
- Division of Cardiovascular Medicine, Stanford University School of Medicine, 300 Pasteur Drive Room H2103, Stanford, CA, 94305, USA.,Stanford Cardiovascular Institute, Stanford, CA, USA
| | - Daniel A Brenner
- Division of Cardiovascular Medicine, Stanford University School of Medicine, 300 Pasteur Drive Room H2103, Stanford, CA, 94305, USA.,Stanford Cardiovascular Institute, Stanford, CA, USA.,Kaiser Permanente, Hawaii Region, Moanalua Medical Center, Honolulu, HI, USA
| | - Ryan O'Malley
- Division of Cardiovascular Medicine, Stanford University School of Medicine, 300 Pasteur Drive Room H2103, Stanford, CA, 94305, USA.,Stanford Cardiovascular Institute, Stanford, CA, USA
| | - Ingela Schnittger
- Division of Cardiovascular Medicine, Stanford University School of Medicine, 300 Pasteur Drive Room H2103, Stanford, CA, 94305, USA.,Stanford Cardiovascular Institute, Stanford, CA, USA
| | - Michael Fischbein
- Division of Cardiovascular Medicine, Stanford University School of Medicine, 300 Pasteur Drive Room H2103, Stanford, CA, 94305, USA.,Stanford Cardiovascular Institute, Stanford, CA, USA
| | - D Craig Miller
- Division of Cardiovascular Medicine, Stanford University School of Medicine, 300 Pasteur Drive Room H2103, Stanford, CA, 94305, USA.,Stanford Cardiovascular Institute, Stanford, CA, USA
| | - Alan C Yeung
- Division of Cardiovascular Medicine, Stanford University School of Medicine, 300 Pasteur Drive Room H2103, Stanford, CA, 94305, USA.,Stanford Cardiovascular Institute, Stanford, CA, USA
| | - David Liang
- Division of Cardiovascular Medicine, Stanford University School of Medicine, 300 Pasteur Drive Room H2103, Stanford, CA, 94305, USA.,Stanford Cardiovascular Institute, Stanford, CA, USA
| | - Francois Haddad
- Division of Cardiovascular Medicine, Stanford University School of Medicine, 300 Pasteur Drive Room H2103, Stanford, CA, 94305, USA.,Stanford Cardiovascular Institute, Stanford, CA, USA
| | - William F Fearon
- Division of Cardiovascular Medicine, Stanford University School of Medicine, 300 Pasteur Drive Room H2103, Stanford, CA, 94305, USA. .,Stanford Cardiovascular Institute, Stanford, CA, USA.
| |
Collapse
|
225
|
Association of frailty status with acute kidney injury and mortality after transcatheter aortic valve replacement: A systematic review and meta-analysis. PLoS One 2017; 12:e0177157. [PMID: 28545062 PMCID: PMC5436661 DOI: 10.1371/journal.pone.0177157] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2016] [Accepted: 04/24/2017] [Indexed: 01/08/2023] Open
Abstract
Objective Frailty is a common condition in patients with severe aortic stenosis (AS) undergoing transcatheter aortic valve replacement (TAVR). The aim of this systematic review was to assess the impact of frailty status on acute kidney injury (AKI) and mortality after TAVR. Methods A systematic literature search was conducted using MEDLINE, EMBASE, and Cochrane databases from the inception through November 2016. The protocol for this study is registered with PROSPERO (International Prospective Register of Systematic Reviews; no. CRD42016052350). Studies that reported odds ratios, relative risks or hazard ratios comparing the risk of AKI after TAVR in frail vs. non-frail patients were included. Mortality risk was evaluated among the studies that reported AKI-related outcomes. Pooled risk ratios (RR) and 95% confidence interval (CI) were calculated using a random-effect, generic inverse variance method. Results Eight cohort studies with a total of 10,498 patients were identified and included in the meta-analysis. The pooled RR of AKI after TAVR among the frail patients was 1.19 (95% CI 0.97–1.46, I2 = 0), compared with non-frail patients. When the meta-analysis was restricted only to studies with standardized AKI diagnosis according to Valve Academic Research Consortium (VARC)-2 criteria, the pooled RRs of AKI in frail patients was 1.16 (95% CI 0.91–1.47, I2 = 0). Within the selected studies, frailty status was significantly associated with increased mortality (RR 2.01; 95% CI 1.44–2.80, I2 = 58). Conclusion The findings from our study suggest no significant association between frailty status and AKI after TAVR. However, frailty status is associated with mortality after TAVR and may aid appropriate patient selection for TAVR.
Collapse
|
226
|
Bleiziffer S, Bosmans J, Brecker S, Gerckens U, Wenaweser P, Tamburino C, Linke A. Insights on mid-term TAVR performance: 3-year clinical and echocardiographic results from the CoreValve ADVANCE study. Clin Res Cardiol 2017; 106:784-795. [PMID: 28484830 DOI: 10.1007/s00392-017-1120-3] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/06/2017] [Accepted: 04/25/2017] [Indexed: 11/28/2022]
Abstract
BACKGROUND Extensive evidence relating to transcatheter aortic valve replacement (TAVR) has accumulated in recent years, but mid-term outcomes are less reported. We investigated 996 patients after implantation of the CoreValve prosthesis for severe aortic stenosis in a real-world setting. OBJECTIVE To report clinical and echocardiographic 3-year results from the ADVANCE study. METHODS ADVANCE is a prospective, multicenter, fully monitored, nonrandomized clinical study. This analysis assessed valve-related events, predictors of early and mid-term mortality after TAVR, and systolic and diastolic prosthesis performance over 3 years. RESULTS Three years after TAVR, the rate of major adverse cardiac/cerebrovascular events was 38.5%. All-cause mortality was 33.7%; cardiovascular mortality, 22.3%; VARC-1 stroke, 6.5%; and New York Heart Association class III/IV, 19.5%. Mean effective orifice area was consistently 1.7 cm2 from discharge to 3 years, and average mean aortic valve gradient remained ≤10 mmHg. At 3 years, 12.6% of patients had moderate and none had severe paravalvular regurgitation. Multivariable analysis identified Society of Thoracic Surgeons (STS) score, device migration, prior atrial fibrillation, and major vascular complication as predictors of early mortality. Predictors of mid-term mortality included male gender, STS score, history of chronic obstructive pulmonary disease, history of cancer, stroke, life-threatening/disabling or major bleeding, and valve deterioration. CONCLUSIONS Our 3-year data demonstrate significant hemodynamic benefits and durable symptom relief after CoreValve prosthesis implantation. Postprocedural patient management should be carefully considered, since postprocedural valve-related events were identified as independent predictors of mid-term mortality. TRIAL REGISTRATION ClinicalTrials.gov, NCT01074658.
Collapse
Affiliation(s)
- Sabine Bleiziffer
- Clinic for Cardiovascular Surgery, Department of Cardiovascular Surgery, German Heart Center, Technical University Munich, Lazarettstr. 36, 80636, Munich, Germany.
| | - Johan Bosmans
- Cardiovascular Diseases Department, Antwerp University Hospital, Edegem, Belgium
| | - Stephen Brecker
- Cardiology Clinical Academic Group, St. George's Hospital, London, UK
| | - Ulrich Gerckens
- Cardiology Department, Gemeinschaftskrankenhaus, Bonn, Germany
| | - Peter Wenaweser
- Department of Cardiology, Bern University Hospital, Bern, Switzerland
| | - Corrado Tamburino
- Cardiology Unit, Ferrarotto Hospital, University of Catania, Catania, Italy
| | - Axel Linke
- Department of Internal Medicine and Cardiology, University of Leipzig Heart Center, Leipzig, Germany
| | | |
Collapse
|
227
|
Okoh AK, Chauhan D, Kang N, Haik N, Merlo A, Cohen M, Haik B, Chen C, Russo MJ. The impact of frailty status on clinical and functional outcomes after transcatheter aortic valve replacement in nonagenarians with severe aortic stenosis. Catheter Cardiovasc Interv 2017; 90:1000-1006. [PMID: 28463403 DOI: 10.1002/ccd.27083] [Citation(s) in RCA: 35] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/06/2017] [Revised: 03/13/2017] [Accepted: 03/25/2017] [Indexed: 11/11/2022]
Abstract
BACKGROUND The impact of frailty status on TAVR outcomes in nonagenarians is unknown. The present study aims to investigate the impact of frailty status on procedural outcomes and overall survival in nonagenarians after TAVR. METHODS A frailty score (FS) was derived by using preoperative grip strength, gait speed, serum albumin, and daily activities. Patients were divided into two groups: Frail (FS ≥ 3/4) and Non-Frail (FS <3/4). Health status was assessed using the 12-item Kansas City Cardiomyopathy Questionnaire (KCCQ). Baseline demographic and clinical characteristics were compared in both groups. The effect of frailty status on outcomes was investigated. Cox regression analyses were performed to determine predictors of overall all-cause mortality. Kaplan-Meier survival curves were used to estimate survival. RESULTS Seventy-five patients >90 years underwent full assessment for frailty status. There was a significant improvement in overall health status of non-frail patients (mean difference: 11.03, P = 0.032). Unadjusted 30-day and 2-year mortality rates were higher in the frail group than the non-frail group. (14% vs. 2% P = 0.059; 31% vs. 9% P = 0.018). Kaplan-Meier estimated all-cause mortality to be significantly higher in the frail group (log-rank test; P = 0.042). Frailty status was independently associated with increased mortality (hazard ratio: 1.84, 95% C.I: 1.06-3.17; P = 0.028) after TAVR. CONCLUSION Among nonagenarians selected to undergo TAVR for severe aortic stenosis, a considerable number are frail. Nonfrail patients report a significant improvement in overall health status in the short term. Worse frailty is strongly associated with diminished long-term survival. © 2017 Wiley Periodicals, Inc.
Collapse
Affiliation(s)
- Alexis K Okoh
- Department of Cardiothoracic Surgery, RWJ Barnabas Health-Newark Beth Israel Medical Center, Newark, New Jersey
| | - Dhaval Chauhan
- Department of Cardiothoracic Surgery, RWJ Barnabas Health-Newark Beth Israel Medical Center, Newark, New Jersey
| | - Nathan Kang
- Department of Cardiothoracic Surgery, RWJ Barnabas Health-Newark Beth Israel Medical Center, Newark, New Jersey
| | - Nicky Haik
- Department of Cardiothoracic Surgery, RWJ Barnabas Health-Newark Beth Israel Medical Center, Newark, New Jersey
| | - Aurelie Merlo
- Department of Cardiothoracic Surgery, RWJ Barnabas Health-Newark Beth Israel Medical Center, Newark, New Jersey
| | - Mark Cohen
- Department of Cardiothoracic Surgery, RWJ Barnabas Health-Newark Beth Israel Medical Center, Newark, New Jersey
| | - Bruce Haik
- Department of Cardiothoracic Surgery, RWJ Barnabas Health-Newark Beth Israel Medical Center, Newark, New Jersey
| | - Chunguang Chen
- Department of Cardiothoracic Surgery, RWJ Barnabas Health-Newark Beth Israel Medical Center, Newark, New Jersey
| | - Mark J Russo
- Department of Cardiothoracic Surgery, RWJ Barnabas Health-Newark Beth Israel Medical Center, Newark, New Jersey
| |
Collapse
|
228
|
Veronese N, Cereda E, Stubbs B, Solmi M, Luchini C, Manzato E, Sergi G, Manu P, Harris T, Fontana L, Strandberg T, Amieva H, Dumurgier J, Elbaz A, Tzourio C, Eicholzer M, Rohrmann S, Moretti C, D'Ascenzo F, Quadri G, Polidoro A, Lourenço RA, Moreira VG, Sanchis J, Scotti V, Maggi S, Correll CU. Risk of cardiovascular disease morbidity and mortality in frail and pre-frail older adults: Results from a meta-analysis and exploratory meta-regression analysis. Ageing Res Rev 2017; 35:63-73. [PMID: 28143778 PMCID: PMC6047747 DOI: 10.1016/j.arr.2017.01.003] [Citation(s) in RCA: 189] [Impact Index Per Article: 23.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2016] [Revised: 12/22/2016] [Accepted: 01/23/2017] [Indexed: 12/30/2022]
Abstract
Frailty is common and associated with poorer outcomes in the elderly, but its role as potential cardiovascular disease (CVD) risk factor requires clarification. We thus aimed to meta-analytically evaluate the evidence of frailty and pre-frailty as risk factors for CVD. Two reviewers selected all studies comparing data about CVD prevalence or incidence rates between frail/pre-frail vs. robust. The association between frailty status and CVD in cross-sectional studies was explored by calculating and pooling crude and adjusted odds ratios (ORs) ±95% confidence intervals (CIs); the data from longitudinal studies were pooled using the adjusted hazard ratios (HRs). Eighteen cohorts with a total of 31,343 participants were meta-analyzed. Using estimates from 10 cross-sectional cohorts, both frailty and pre-frailty were associated with higher odds of CVD than robust participants. Longitudinal data were obtained from 6 prospective cohort studies. After a median follow-up of 4.4 years, we identified an increased risk for faster onset of any-type CVD in the frail (HR=1.70 [95%CI, 1.18-2.45]; I2=66%) and pre-frail (HR=1.23 [95%CI, 1.07-1.36]; I2=67%) vs. robust groups. Similar results were apparent for time to CVD mortality in the frail and pre-frail groups. In conclusion, frailty and pre-frailty constitute addressable and independent risk factors for CVD in older adults.
Collapse
Affiliation(s)
- Nicola Veronese
- Department of Medicine (DIMED), Geriatrics Division, University of Padova, Italy; Institute for Clinical Research and Education in Medicine (IREM), Padova, Italy; National Research Council, Neuroscience Institute-Aging Branch, Padova, Italy.
| | - Emanuele Cereda
- Nutrition and Dietetics Service, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
| | - Brendon Stubbs
- Physiotherapy Department, South London and Maudsley NHS FoundationTrust, Denmark Hill, London SE5 8AZ, United Kingdom; Health Service and Population Research Department, Institute of Psychiatry, King's College London, De Crespigny Park, London SE5 8AF, United Kingdom; Health, Social Care and Education, Anglia Ruskin University, Chelmsford, United Kingdom
| | - Marco Solmi
- Institute for Clinical Research and Education in Medicine (IREM), Padova, Italy; Department of Neurosciences, University of Padova, Padova, Italy; National Health Care System, Monselice, Padova Local Unit ULSS 17, Italy
| | - Claudio Luchini
- Department of Pathology and Diagnostics, University and Hospital Trust of Verona, Verona, Italy; Surgical Pathology Unit, Santa Chiara Hospital, Trento, Italy
| | - Enzo Manzato
- Department of Medicine (DIMED), Geriatrics Division, University of Padova, Italy; National Research Council, Neuroscience Institute-Aging Branch, Padova, Italy
| | - Giuseppe Sergi
- Department of Medicine (DIMED), Geriatrics Division, University of Padova, Italy
| | - Peter Manu
- South Oaks Hospital, Northwell Health,400 Sunsrise Highway, Amityville, NY 11701, USA
| | - Tamara Harris
- Laboratory of Epidemiology and Population Sciences, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA
| | - Luigi Fontana
- Division of Geriatrics and Nutritional Sciences and Center for Human Nutrition, Washington University School of Medicine, St. Louis, MO, USA; Department of Clinical and Experimental Sciences, Brescia University, Brescia, Italy; CEINGE Biotecnologie Avanzate, Napoli, Italy
| | - Timo Strandberg
- University of Helsinki and Helsinki University Hospital, Helsinki, Finland; University of Oulu,Center for Life Course Health Research, Oulu, Finland
| | - Helene Amieva
- Centre de Recherche Inserm, Bordeaux, France; University Victor Segalen Bordeaux 2, Bordeaux, France
| | - Julien Dumurgier
- CMRR Paris Nord AP-HP, Groupe Hospitalier Lariboisière Fernand-Widal Saint-Louis, INSERM, U942, Université Paris Diderot, Sorbonne Paris Cité, UMRS 942, Paris, France
| | - Alexis Elbaz
- CESP, Univ. Paris-Sud, UVSQ, INSERM, Université Paris-Saclay, Villejuif, France
| | | | - Monika Eicholzer
- University of Zurich, Epidemiology, Biostatistics and Prevention Institute, Division of Chronic Disease Epidemiology, Hirschengraben 84, CH-8001 Zurich, Switzerland
| | - Sabine Rohrmann
- University of Zurich, Epidemiology, Biostatistics and Prevention Institute, Division of Chronic Disease Epidemiology, Hirschengraben 84, CH-8001 Zurich, Switzerland
| | - Claudio Moretti
- Division of Cardiology, Department of Science, Città della Salute e della Scienza, Turin, Italy
| | - Fabrizio D'Ascenzo
- Division of Cardiology, Department of Science, Città della Salute e della Scienza, Turin, Italy
| | - Giorgio Quadri
- Division of Cardiology, Department of Science, Città della Salute e della Scienza, Turin, Italy
| | - Alessandro Polidoro
- Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy
| | - Roberto Alves Lourenço
- Department of Internal Medicine, Faculty of Medical Sciences, State University of Rio de Janeiro, Rio de Janeiro, Brazil
| | - Virgilio Garcia Moreira
- Department of Internal Medicine, Faculty of Medical Sciences, State University of Rio de Janeiro, Rio de Janeiro, Brazil
| | - Juan Sanchis
- Department of Cardiology, Hospital Clínico Universitario, School of Medicine, University of Valencia, Valencia, (CIBER-CV), Spain
| | - Valeria Scotti
- Clinical Epidemiology and Biometric Unit, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy
| | - Stefania Maggi
- National Research Council, Neuroscience Institute-Aging Branch, Padova, Italy
| | - Christoph U Correll
- The Zucker Hillside Hospital, Psychiatry Research, Northwell Health, Glen Oaks, New York, USA; Hofstra Northwell School of Medicine, Hempstead, NY, USA; The Feinstein Institute for Medical Research, Manhasset, NY, USA; Albert Einstein College of Medicine, Bronx, NY, USA
| |
Collapse
|
229
|
Pulignano G, Gulizia MM, Baldasseroni S, Bedogni F, Cioffi G, Indolfi C, Romeo F, Murrone A, Musumeci F, Parolari A, Patanè L, Pino PG, Mongiardo A, Spaccarotella C, Di Bartolomeo R, Musumeci G. ANMCO/SIC/SICI-GISE/SICCH Executive Summary of Consensus Document on Risk Stratification in elderly patients with aortic stenosis before surgery or transcatheter aortic valve replacement. Eur Heart J Suppl 2017; 19:D354-D369. [PMID: 28751850 PMCID: PMC5520760 DOI: 10.1093/eurheartj/sux012] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
Aortic stenosis is one of the most frequent valvular diseases in developed countries, and its impact on public health resources and assistance is increasing. A substantial proportion of elderly people with severe aortic stenosis is not eligible to surgery because of the advanced age, frailty, and multiple co-morbidities. Transcatheter aortic valve implantation (TAVI) enables the treatment of very elderly patients at high or prohibitive surgical risk considered ineligible for surgery and with an acceptable life expectancy. However, a significant percentage of patients die or show no improvement in quality of life (QOL) in the follow-up. In the decision-making process, it is important to determine: (i) whether and how much frailty of the patient influences the risk of procedures; (ii) how the QOL and the individual patient's survival are influenced by aortic valve disease or from other associated conditions; and (iii) whether a geriatric specialist intervention to evaluate and correct frailty or other diseases with their potential or already manifest disabilities can improve the outcome of surgery or TAVI. Consequently, in addition to risk stratification with conventional tools, a number of factors including multi-morbidity, disability, frailty, and cognitive function should be considered, in order to assess the expected benefit of both surgery and TAVI. The pre-operative optimization through a multidisciplinary approach with a Heart Team can counteract the multiple damage (cardiac, neurological, muscular, respiratory, and kidney) that can potentially aggravate the reduced physiological reserves characteristic of frailty. The systematic application in clinical practice of multidimensional assessment instruments of frailty and cognitive function in the screening and the adoption of specific care pathways should facilitate this task.
Collapse
Affiliation(s)
- Giovanni Pulignano
- Cardiology Department 1, Ospedale San Camillo-Forlanini, Via O. Regnoli, 8 00152 Rome, Italy
| | - Michele Massimo Gulizia
- Cardiology Department, Ospedale Garibaldi-Nesima, Azienda di Rilievo Nazionale e Alta Specializzazione "Garibaldi" Catania, Italy
| | | | - Francesco Bedogni
- CCU-Cardiology Unit, IRCCS Policlinico San Donato, San Donato Milanese (Milano), Italy
| | - Giovanni Cioffi
- Cardiology and Medicine Unit, Casa di Cura Villa Bianca, Trento, Italy
| | - Ciro Indolfi
- Cardiology Unit- Campus Universitario, Azienda Ospedaliera Universitaria Mater Domini, Catanzaro, Italy
| | - Francesco Romeo
- Cardiology and Interventional Cardiology Department, Policlinico "Tor Vergata", Rome, Italy
| | - Adriano Murrone
- Cardiology and Cardiovascular Pathophysiology Department, Azienda Ospedaliera di Perugia, Perugia, Italy
| | | | - Alessandro Parolari
- Heart Surgery Unit, Centro Cardiologico Monzino IRCCS, Università degli Studi, Milano, Italy
| | - Leonardo Patanè
- Cardiology Cardiac Surgery Department (Centro Cuore), Centro Clinico Diagnostico G.B. Morgagni, Pedara (Catania), Italy
| | | | - Annalisa Mongiardo
- Cardiology Unit- Campus Universitario, Azienda Ospedaliera Universitaria Mater Domini, Catanzaro, Italy
| | - Carmen Spaccarotella
- Cardiology Unit- Campus Universitario, Azienda Ospedaliera Universitaria Mater Domini, Catanzaro, Italy
| | | | | |
Collapse
|
230
|
Reardon MJ, Van Mieghem NM, Popma JJ, Kleiman NS, Søndergaard L, Mumtaz M, Adams DH, Deeb GM, Maini B, Gada H, Chetcuti S, Gleason T, Heiser J, Lange R, Merhi W, Oh JK, Olsen PS, Piazza N, Williams M, Windecker S, Yakubov SJ, Grube E, Makkar R, Lee JS, Conte J, Vang E, Nguyen H, Chang Y, Mugglin AS, Serruys PWJC, Kappetein AP. Surgical or Transcatheter Aortic-Valve Replacement in Intermediate-Risk Patients. N Engl J Med 2017; 376:1321-1331. [PMID: 28304219 DOI: 10.1056/nejmoa1700456] [Citation(s) in RCA: 2173] [Impact Index Per Article: 271.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
BACKGROUND Although transcatheter aortic-valve replacement (TAVR) is an accepted alternative to surgery in patients with severe aortic stenosis who are at high surgical risk, less is known about comparative outcomes among patients with aortic stenosis who are at intermediate surgical risk. METHODS We evaluated the clinical outcomes in intermediate-risk patients with severe, symptomatic aortic stenosis in a randomized trial comparing TAVR (performed with the use of a self-expanding prosthesis) with surgical aortic-valve replacement. The primary end point was a composite of death from any cause or disabling stroke at 24 months in patients undergoing attempted aortic-valve replacement. We used Bayesian analytical methods (with a margin of 0.07) to evaluate the noninferiority of TAVR as compared with surgical valve replacement. RESULTS A total of 1746 patients underwent randomization at 87 centers. Of these patients, 1660 underwent an attempted TAVR or surgical procedure. The mean (±SD) age of the patients was 79.8±6.2 years, and all were at intermediate risk for surgery (Society of Thoracic Surgeons Predicted Risk of Mortality, 4.5±1.6%). At 24 months, the estimated incidence of the primary end point was 12.6% in the TAVR group and 14.0% in the surgery group (95% credible interval [Bayesian analysis] for difference, -5.2 to 2.3%; posterior probability of noninferiority, >0.999). Surgery was associated with higher rates of acute kidney injury, atrial fibrillation, and transfusion requirements, whereas TAVR had higher rates of residual aortic regurgitation and need for pacemaker implantation. TAVR resulted in lower mean gradients and larger aortic-valve areas than surgery. Structural valve deterioration at 24 months did not occur in either group. CONCLUSIONS TAVR was a noninferior alternative to surgery in patients with severe aortic stenosis at intermediate surgical risk, with a different pattern of adverse events associated with each procedure. (Funded by Medtronic; SURTAVI ClinicalTrials.gov number, NCT01586910 .).
Collapse
Affiliation(s)
- Michael J Reardon
- From Methodist DeBakey Heart and Vascular Center, Houston (M.J.R., N.S.K.); Erasmus University Medical Center, Rotterdam, the Netherlands (N.M.V.M., P.W.J.C.S., A.P.K.); Beth Israel Deaconess Medical Center, Boston (J.J.P.); the Heart Center, Rigshospitalet, Copenhagen (L.S., P.S.O.); PinnacleHealth Hospitals, Harrisburg (M.M., H.G.), and University of Pittsburgh Medical Center, Pittsburgh (T.G., J.S.L.) - both in Pennsylvania; Mount Sinai Health System (D.H.A.) and New York University Langone Medical Center (M.W.) - both in New York; University of Michigan, Ann Arbor (G.M.D., S.C.), and Spectrum Health Hospitals, Grand Rapids (J.H., W.M.) - both in Michigan; Tenet Healthcare, Delray Beach, FL (B.M.); German Heart Center Munich, Munich (R.L.), and Siegburg Heart Center, Siegburg (E.G.) - both in Germany; Mayo Clinic, Rochester (J.K.O.), Medtronic, Minneapolis (E.V., H.N., Y.C.), and Paradigm Biostatistics, Anoka (A.S.M.) - all in Minnesota; McGill University Medical Centre, Montreal (N.P.); University Hospital Bern, Bern, Switzerland (S.W.); Riverside Methodist Hospital, Columbus, OH (S.J.Y.); Cedars-Sinai Medical Center, Los Angeles (R.M.); and Johns Hopkins University, Baltimore (J.C.)
| | - Nicolas M Van Mieghem
- From Methodist DeBakey Heart and Vascular Center, Houston (M.J.R., N.S.K.); Erasmus University Medical Center, Rotterdam, the Netherlands (N.M.V.M., P.W.J.C.S., A.P.K.); Beth Israel Deaconess Medical Center, Boston (J.J.P.); the Heart Center, Rigshospitalet, Copenhagen (L.S., P.S.O.); PinnacleHealth Hospitals, Harrisburg (M.M., H.G.), and University of Pittsburgh Medical Center, Pittsburgh (T.G., J.S.L.) - both in Pennsylvania; Mount Sinai Health System (D.H.A.) and New York University Langone Medical Center (M.W.) - both in New York; University of Michigan, Ann Arbor (G.M.D., S.C.), and Spectrum Health Hospitals, Grand Rapids (J.H., W.M.) - both in Michigan; Tenet Healthcare, Delray Beach, FL (B.M.); German Heart Center Munich, Munich (R.L.), and Siegburg Heart Center, Siegburg (E.G.) - both in Germany; Mayo Clinic, Rochester (J.K.O.), Medtronic, Minneapolis (E.V., H.N., Y.C.), and Paradigm Biostatistics, Anoka (A.S.M.) - all in Minnesota; McGill University Medical Centre, Montreal (N.P.); University Hospital Bern, Bern, Switzerland (S.W.); Riverside Methodist Hospital, Columbus, OH (S.J.Y.); Cedars-Sinai Medical Center, Los Angeles (R.M.); and Johns Hopkins University, Baltimore (J.C.)
| | - Jeffrey J Popma
- From Methodist DeBakey Heart and Vascular Center, Houston (M.J.R., N.S.K.); Erasmus University Medical Center, Rotterdam, the Netherlands (N.M.V.M., P.W.J.C.S., A.P.K.); Beth Israel Deaconess Medical Center, Boston (J.J.P.); the Heart Center, Rigshospitalet, Copenhagen (L.S., P.S.O.); PinnacleHealth Hospitals, Harrisburg (M.M., H.G.), and University of Pittsburgh Medical Center, Pittsburgh (T.G., J.S.L.) - both in Pennsylvania; Mount Sinai Health System (D.H.A.) and New York University Langone Medical Center (M.W.) - both in New York; University of Michigan, Ann Arbor (G.M.D., S.C.), and Spectrum Health Hospitals, Grand Rapids (J.H., W.M.) - both in Michigan; Tenet Healthcare, Delray Beach, FL (B.M.); German Heart Center Munich, Munich (R.L.), and Siegburg Heart Center, Siegburg (E.G.) - both in Germany; Mayo Clinic, Rochester (J.K.O.), Medtronic, Minneapolis (E.V., H.N., Y.C.), and Paradigm Biostatistics, Anoka (A.S.M.) - all in Minnesota; McGill University Medical Centre, Montreal (N.P.); University Hospital Bern, Bern, Switzerland (S.W.); Riverside Methodist Hospital, Columbus, OH (S.J.Y.); Cedars-Sinai Medical Center, Los Angeles (R.M.); and Johns Hopkins University, Baltimore (J.C.)
| | - Neal S Kleiman
- From Methodist DeBakey Heart and Vascular Center, Houston (M.J.R., N.S.K.); Erasmus University Medical Center, Rotterdam, the Netherlands (N.M.V.M., P.W.J.C.S., A.P.K.); Beth Israel Deaconess Medical Center, Boston (J.J.P.); the Heart Center, Rigshospitalet, Copenhagen (L.S., P.S.O.); PinnacleHealth Hospitals, Harrisburg (M.M., H.G.), and University of Pittsburgh Medical Center, Pittsburgh (T.G., J.S.L.) - both in Pennsylvania; Mount Sinai Health System (D.H.A.) and New York University Langone Medical Center (M.W.) - both in New York; University of Michigan, Ann Arbor (G.M.D., S.C.), and Spectrum Health Hospitals, Grand Rapids (J.H., W.M.) - both in Michigan; Tenet Healthcare, Delray Beach, FL (B.M.); German Heart Center Munich, Munich (R.L.), and Siegburg Heart Center, Siegburg (E.G.) - both in Germany; Mayo Clinic, Rochester (J.K.O.), Medtronic, Minneapolis (E.V., H.N., Y.C.), and Paradigm Biostatistics, Anoka (A.S.M.) - all in Minnesota; McGill University Medical Centre, Montreal (N.P.); University Hospital Bern, Bern, Switzerland (S.W.); Riverside Methodist Hospital, Columbus, OH (S.J.Y.); Cedars-Sinai Medical Center, Los Angeles (R.M.); and Johns Hopkins University, Baltimore (J.C.)
| | - Lars Søndergaard
- From Methodist DeBakey Heart and Vascular Center, Houston (M.J.R., N.S.K.); Erasmus University Medical Center, Rotterdam, the Netherlands (N.M.V.M., P.W.J.C.S., A.P.K.); Beth Israel Deaconess Medical Center, Boston (J.J.P.); the Heart Center, Rigshospitalet, Copenhagen (L.S., P.S.O.); PinnacleHealth Hospitals, Harrisburg (M.M., H.G.), and University of Pittsburgh Medical Center, Pittsburgh (T.G., J.S.L.) - both in Pennsylvania; Mount Sinai Health System (D.H.A.) and New York University Langone Medical Center (M.W.) - both in New York; University of Michigan, Ann Arbor (G.M.D., S.C.), and Spectrum Health Hospitals, Grand Rapids (J.H., W.M.) - both in Michigan; Tenet Healthcare, Delray Beach, FL (B.M.); German Heart Center Munich, Munich (R.L.), and Siegburg Heart Center, Siegburg (E.G.) - both in Germany; Mayo Clinic, Rochester (J.K.O.), Medtronic, Minneapolis (E.V., H.N., Y.C.), and Paradigm Biostatistics, Anoka (A.S.M.) - all in Minnesota; McGill University Medical Centre, Montreal (N.P.); University Hospital Bern, Bern, Switzerland (S.W.); Riverside Methodist Hospital, Columbus, OH (S.J.Y.); Cedars-Sinai Medical Center, Los Angeles (R.M.); and Johns Hopkins University, Baltimore (J.C.)
| | - Mubashir Mumtaz
- From Methodist DeBakey Heart and Vascular Center, Houston (M.J.R., N.S.K.); Erasmus University Medical Center, Rotterdam, the Netherlands (N.M.V.M., P.W.J.C.S., A.P.K.); Beth Israel Deaconess Medical Center, Boston (J.J.P.); the Heart Center, Rigshospitalet, Copenhagen (L.S., P.S.O.); PinnacleHealth Hospitals, Harrisburg (M.M., H.G.), and University of Pittsburgh Medical Center, Pittsburgh (T.G., J.S.L.) - both in Pennsylvania; Mount Sinai Health System (D.H.A.) and New York University Langone Medical Center (M.W.) - both in New York; University of Michigan, Ann Arbor (G.M.D., S.C.), and Spectrum Health Hospitals, Grand Rapids (J.H., W.M.) - both in Michigan; Tenet Healthcare, Delray Beach, FL (B.M.); German Heart Center Munich, Munich (R.L.), and Siegburg Heart Center, Siegburg (E.G.) - both in Germany; Mayo Clinic, Rochester (J.K.O.), Medtronic, Minneapolis (E.V., H.N., Y.C.), and Paradigm Biostatistics, Anoka (A.S.M.) - all in Minnesota; McGill University Medical Centre, Montreal (N.P.); University Hospital Bern, Bern, Switzerland (S.W.); Riverside Methodist Hospital, Columbus, OH (S.J.Y.); Cedars-Sinai Medical Center, Los Angeles (R.M.); and Johns Hopkins University, Baltimore (J.C.)
| | - David H Adams
- From Methodist DeBakey Heart and Vascular Center, Houston (M.J.R., N.S.K.); Erasmus University Medical Center, Rotterdam, the Netherlands (N.M.V.M., P.W.J.C.S., A.P.K.); Beth Israel Deaconess Medical Center, Boston (J.J.P.); the Heart Center, Rigshospitalet, Copenhagen (L.S., P.S.O.); PinnacleHealth Hospitals, Harrisburg (M.M., H.G.), and University of Pittsburgh Medical Center, Pittsburgh (T.G., J.S.L.) - both in Pennsylvania; Mount Sinai Health System (D.H.A.) and New York University Langone Medical Center (M.W.) - both in New York; University of Michigan, Ann Arbor (G.M.D., S.C.), and Spectrum Health Hospitals, Grand Rapids (J.H., W.M.) - both in Michigan; Tenet Healthcare, Delray Beach, FL (B.M.); German Heart Center Munich, Munich (R.L.), and Siegburg Heart Center, Siegburg (E.G.) - both in Germany; Mayo Clinic, Rochester (J.K.O.), Medtronic, Minneapolis (E.V., H.N., Y.C.), and Paradigm Biostatistics, Anoka (A.S.M.) - all in Minnesota; McGill University Medical Centre, Montreal (N.P.); University Hospital Bern, Bern, Switzerland (S.W.); Riverside Methodist Hospital, Columbus, OH (S.J.Y.); Cedars-Sinai Medical Center, Los Angeles (R.M.); and Johns Hopkins University, Baltimore (J.C.)
| | - G Michael Deeb
- From Methodist DeBakey Heart and Vascular Center, Houston (M.J.R., N.S.K.); Erasmus University Medical Center, Rotterdam, the Netherlands (N.M.V.M., P.W.J.C.S., A.P.K.); Beth Israel Deaconess Medical Center, Boston (J.J.P.); the Heart Center, Rigshospitalet, Copenhagen (L.S., P.S.O.); PinnacleHealth Hospitals, Harrisburg (M.M., H.G.), and University of Pittsburgh Medical Center, Pittsburgh (T.G., J.S.L.) - both in Pennsylvania; Mount Sinai Health System (D.H.A.) and New York University Langone Medical Center (M.W.) - both in New York; University of Michigan, Ann Arbor (G.M.D., S.C.), and Spectrum Health Hospitals, Grand Rapids (J.H., W.M.) - both in Michigan; Tenet Healthcare, Delray Beach, FL (B.M.); German Heart Center Munich, Munich (R.L.), and Siegburg Heart Center, Siegburg (E.G.) - both in Germany; Mayo Clinic, Rochester (J.K.O.), Medtronic, Minneapolis (E.V., H.N., Y.C.), and Paradigm Biostatistics, Anoka (A.S.M.) - all in Minnesota; McGill University Medical Centre, Montreal (N.P.); University Hospital Bern, Bern, Switzerland (S.W.); Riverside Methodist Hospital, Columbus, OH (S.J.Y.); Cedars-Sinai Medical Center, Los Angeles (R.M.); and Johns Hopkins University, Baltimore (J.C.)
| | - Brijeshwar Maini
- From Methodist DeBakey Heart and Vascular Center, Houston (M.J.R., N.S.K.); Erasmus University Medical Center, Rotterdam, the Netherlands (N.M.V.M., P.W.J.C.S., A.P.K.); Beth Israel Deaconess Medical Center, Boston (J.J.P.); the Heart Center, Rigshospitalet, Copenhagen (L.S., P.S.O.); PinnacleHealth Hospitals, Harrisburg (M.M., H.G.), and University of Pittsburgh Medical Center, Pittsburgh (T.G., J.S.L.) - both in Pennsylvania; Mount Sinai Health System (D.H.A.) and New York University Langone Medical Center (M.W.) - both in New York; University of Michigan, Ann Arbor (G.M.D., S.C.), and Spectrum Health Hospitals, Grand Rapids (J.H., W.M.) - both in Michigan; Tenet Healthcare, Delray Beach, FL (B.M.); German Heart Center Munich, Munich (R.L.), and Siegburg Heart Center, Siegburg (E.G.) - both in Germany; Mayo Clinic, Rochester (J.K.O.), Medtronic, Minneapolis (E.V., H.N., Y.C.), and Paradigm Biostatistics, Anoka (A.S.M.) - all in Minnesota; McGill University Medical Centre, Montreal (N.P.); University Hospital Bern, Bern, Switzerland (S.W.); Riverside Methodist Hospital, Columbus, OH (S.J.Y.); Cedars-Sinai Medical Center, Los Angeles (R.M.); and Johns Hopkins University, Baltimore (J.C.)
| | - Hemal Gada
- From Methodist DeBakey Heart and Vascular Center, Houston (M.J.R., N.S.K.); Erasmus University Medical Center, Rotterdam, the Netherlands (N.M.V.M., P.W.J.C.S., A.P.K.); Beth Israel Deaconess Medical Center, Boston (J.J.P.); the Heart Center, Rigshospitalet, Copenhagen (L.S., P.S.O.); PinnacleHealth Hospitals, Harrisburg (M.M., H.G.), and University of Pittsburgh Medical Center, Pittsburgh (T.G., J.S.L.) - both in Pennsylvania; Mount Sinai Health System (D.H.A.) and New York University Langone Medical Center (M.W.) - both in New York; University of Michigan, Ann Arbor (G.M.D., S.C.), and Spectrum Health Hospitals, Grand Rapids (J.H., W.M.) - both in Michigan; Tenet Healthcare, Delray Beach, FL (B.M.); German Heart Center Munich, Munich (R.L.), and Siegburg Heart Center, Siegburg (E.G.) - both in Germany; Mayo Clinic, Rochester (J.K.O.), Medtronic, Minneapolis (E.V., H.N., Y.C.), and Paradigm Biostatistics, Anoka (A.S.M.) - all in Minnesota; McGill University Medical Centre, Montreal (N.P.); University Hospital Bern, Bern, Switzerland (S.W.); Riverside Methodist Hospital, Columbus, OH (S.J.Y.); Cedars-Sinai Medical Center, Los Angeles (R.M.); and Johns Hopkins University, Baltimore (J.C.)
| | - Stanley Chetcuti
- From Methodist DeBakey Heart and Vascular Center, Houston (M.J.R., N.S.K.); Erasmus University Medical Center, Rotterdam, the Netherlands (N.M.V.M., P.W.J.C.S., A.P.K.); Beth Israel Deaconess Medical Center, Boston (J.J.P.); the Heart Center, Rigshospitalet, Copenhagen (L.S., P.S.O.); PinnacleHealth Hospitals, Harrisburg (M.M., H.G.), and University of Pittsburgh Medical Center, Pittsburgh (T.G., J.S.L.) - both in Pennsylvania; Mount Sinai Health System (D.H.A.) and New York University Langone Medical Center (M.W.) - both in New York; University of Michigan, Ann Arbor (G.M.D., S.C.), and Spectrum Health Hospitals, Grand Rapids (J.H., W.M.) - both in Michigan; Tenet Healthcare, Delray Beach, FL (B.M.); German Heart Center Munich, Munich (R.L.), and Siegburg Heart Center, Siegburg (E.G.) - both in Germany; Mayo Clinic, Rochester (J.K.O.), Medtronic, Minneapolis (E.V., H.N., Y.C.), and Paradigm Biostatistics, Anoka (A.S.M.) - all in Minnesota; McGill University Medical Centre, Montreal (N.P.); University Hospital Bern, Bern, Switzerland (S.W.); Riverside Methodist Hospital, Columbus, OH (S.J.Y.); Cedars-Sinai Medical Center, Los Angeles (R.M.); and Johns Hopkins University, Baltimore (J.C.)
| | - Thomas Gleason
- From Methodist DeBakey Heart and Vascular Center, Houston (M.J.R., N.S.K.); Erasmus University Medical Center, Rotterdam, the Netherlands (N.M.V.M., P.W.J.C.S., A.P.K.); Beth Israel Deaconess Medical Center, Boston (J.J.P.); the Heart Center, Rigshospitalet, Copenhagen (L.S., P.S.O.); PinnacleHealth Hospitals, Harrisburg (M.M., H.G.), and University of Pittsburgh Medical Center, Pittsburgh (T.G., J.S.L.) - both in Pennsylvania; Mount Sinai Health System (D.H.A.) and New York University Langone Medical Center (M.W.) - both in New York; University of Michigan, Ann Arbor (G.M.D., S.C.), and Spectrum Health Hospitals, Grand Rapids (J.H., W.M.) - both in Michigan; Tenet Healthcare, Delray Beach, FL (B.M.); German Heart Center Munich, Munich (R.L.), and Siegburg Heart Center, Siegburg (E.G.) - both in Germany; Mayo Clinic, Rochester (J.K.O.), Medtronic, Minneapolis (E.V., H.N., Y.C.), and Paradigm Biostatistics, Anoka (A.S.M.) - all in Minnesota; McGill University Medical Centre, Montreal (N.P.); University Hospital Bern, Bern, Switzerland (S.W.); Riverside Methodist Hospital, Columbus, OH (S.J.Y.); Cedars-Sinai Medical Center, Los Angeles (R.M.); and Johns Hopkins University, Baltimore (J.C.)
| | - John Heiser
- From Methodist DeBakey Heart and Vascular Center, Houston (M.J.R., N.S.K.); Erasmus University Medical Center, Rotterdam, the Netherlands (N.M.V.M., P.W.J.C.S., A.P.K.); Beth Israel Deaconess Medical Center, Boston (J.J.P.); the Heart Center, Rigshospitalet, Copenhagen (L.S., P.S.O.); PinnacleHealth Hospitals, Harrisburg (M.M., H.G.), and University of Pittsburgh Medical Center, Pittsburgh (T.G., J.S.L.) - both in Pennsylvania; Mount Sinai Health System (D.H.A.) and New York University Langone Medical Center (M.W.) - both in New York; University of Michigan, Ann Arbor (G.M.D., S.C.), and Spectrum Health Hospitals, Grand Rapids (J.H., W.M.) - both in Michigan; Tenet Healthcare, Delray Beach, FL (B.M.); German Heart Center Munich, Munich (R.L.), and Siegburg Heart Center, Siegburg (E.G.) - both in Germany; Mayo Clinic, Rochester (J.K.O.), Medtronic, Minneapolis (E.V., H.N., Y.C.), and Paradigm Biostatistics, Anoka (A.S.M.) - all in Minnesota; McGill University Medical Centre, Montreal (N.P.); University Hospital Bern, Bern, Switzerland (S.W.); Riverside Methodist Hospital, Columbus, OH (S.J.Y.); Cedars-Sinai Medical Center, Los Angeles (R.M.); and Johns Hopkins University, Baltimore (J.C.)
| | - Rüdiger Lange
- From Methodist DeBakey Heart and Vascular Center, Houston (M.J.R., N.S.K.); Erasmus University Medical Center, Rotterdam, the Netherlands (N.M.V.M., P.W.J.C.S., A.P.K.); Beth Israel Deaconess Medical Center, Boston (J.J.P.); the Heart Center, Rigshospitalet, Copenhagen (L.S., P.S.O.); PinnacleHealth Hospitals, Harrisburg (M.M., H.G.), and University of Pittsburgh Medical Center, Pittsburgh (T.G., J.S.L.) - both in Pennsylvania; Mount Sinai Health System (D.H.A.) and New York University Langone Medical Center (M.W.) - both in New York; University of Michigan, Ann Arbor (G.M.D., S.C.), and Spectrum Health Hospitals, Grand Rapids (J.H., W.M.) - both in Michigan; Tenet Healthcare, Delray Beach, FL (B.M.); German Heart Center Munich, Munich (R.L.), and Siegburg Heart Center, Siegburg (E.G.) - both in Germany; Mayo Clinic, Rochester (J.K.O.), Medtronic, Minneapolis (E.V., H.N., Y.C.), and Paradigm Biostatistics, Anoka (A.S.M.) - all in Minnesota; McGill University Medical Centre, Montreal (N.P.); University Hospital Bern, Bern, Switzerland (S.W.); Riverside Methodist Hospital, Columbus, OH (S.J.Y.); Cedars-Sinai Medical Center, Los Angeles (R.M.); and Johns Hopkins University, Baltimore (J.C.)
| | - William Merhi
- From Methodist DeBakey Heart and Vascular Center, Houston (M.J.R., N.S.K.); Erasmus University Medical Center, Rotterdam, the Netherlands (N.M.V.M., P.W.J.C.S., A.P.K.); Beth Israel Deaconess Medical Center, Boston (J.J.P.); the Heart Center, Rigshospitalet, Copenhagen (L.S., P.S.O.); PinnacleHealth Hospitals, Harrisburg (M.M., H.G.), and University of Pittsburgh Medical Center, Pittsburgh (T.G., J.S.L.) - both in Pennsylvania; Mount Sinai Health System (D.H.A.) and New York University Langone Medical Center (M.W.) - both in New York; University of Michigan, Ann Arbor (G.M.D., S.C.), and Spectrum Health Hospitals, Grand Rapids (J.H., W.M.) - both in Michigan; Tenet Healthcare, Delray Beach, FL (B.M.); German Heart Center Munich, Munich (R.L.), and Siegburg Heart Center, Siegburg (E.G.) - both in Germany; Mayo Clinic, Rochester (J.K.O.), Medtronic, Minneapolis (E.V., H.N., Y.C.), and Paradigm Biostatistics, Anoka (A.S.M.) - all in Minnesota; McGill University Medical Centre, Montreal (N.P.); University Hospital Bern, Bern, Switzerland (S.W.); Riverside Methodist Hospital, Columbus, OH (S.J.Y.); Cedars-Sinai Medical Center, Los Angeles (R.M.); and Johns Hopkins University, Baltimore (J.C.)
| | - Jae K Oh
- From Methodist DeBakey Heart and Vascular Center, Houston (M.J.R., N.S.K.); Erasmus University Medical Center, Rotterdam, the Netherlands (N.M.V.M., P.W.J.C.S., A.P.K.); Beth Israel Deaconess Medical Center, Boston (J.J.P.); the Heart Center, Rigshospitalet, Copenhagen (L.S., P.S.O.); PinnacleHealth Hospitals, Harrisburg (M.M., H.G.), and University of Pittsburgh Medical Center, Pittsburgh (T.G., J.S.L.) - both in Pennsylvania; Mount Sinai Health System (D.H.A.) and New York University Langone Medical Center (M.W.) - both in New York; University of Michigan, Ann Arbor (G.M.D., S.C.), and Spectrum Health Hospitals, Grand Rapids (J.H., W.M.) - both in Michigan; Tenet Healthcare, Delray Beach, FL (B.M.); German Heart Center Munich, Munich (R.L.), and Siegburg Heart Center, Siegburg (E.G.) - both in Germany; Mayo Clinic, Rochester (J.K.O.), Medtronic, Minneapolis (E.V., H.N., Y.C.), and Paradigm Biostatistics, Anoka (A.S.M.) - all in Minnesota; McGill University Medical Centre, Montreal (N.P.); University Hospital Bern, Bern, Switzerland (S.W.); Riverside Methodist Hospital, Columbus, OH (S.J.Y.); Cedars-Sinai Medical Center, Los Angeles (R.M.); and Johns Hopkins University, Baltimore (J.C.)
| | - Peter S Olsen
- From Methodist DeBakey Heart and Vascular Center, Houston (M.J.R., N.S.K.); Erasmus University Medical Center, Rotterdam, the Netherlands (N.M.V.M., P.W.J.C.S., A.P.K.); Beth Israel Deaconess Medical Center, Boston (J.J.P.); the Heart Center, Rigshospitalet, Copenhagen (L.S., P.S.O.); PinnacleHealth Hospitals, Harrisburg (M.M., H.G.), and University of Pittsburgh Medical Center, Pittsburgh (T.G., J.S.L.) - both in Pennsylvania; Mount Sinai Health System (D.H.A.) and New York University Langone Medical Center (M.W.) - both in New York; University of Michigan, Ann Arbor (G.M.D., S.C.), and Spectrum Health Hospitals, Grand Rapids (J.H., W.M.) - both in Michigan; Tenet Healthcare, Delray Beach, FL (B.M.); German Heart Center Munich, Munich (R.L.), and Siegburg Heart Center, Siegburg (E.G.) - both in Germany; Mayo Clinic, Rochester (J.K.O.), Medtronic, Minneapolis (E.V., H.N., Y.C.), and Paradigm Biostatistics, Anoka (A.S.M.) - all in Minnesota; McGill University Medical Centre, Montreal (N.P.); University Hospital Bern, Bern, Switzerland (S.W.); Riverside Methodist Hospital, Columbus, OH (S.J.Y.); Cedars-Sinai Medical Center, Los Angeles (R.M.); and Johns Hopkins University, Baltimore (J.C.)
| | - Nicolo Piazza
- From Methodist DeBakey Heart and Vascular Center, Houston (M.J.R., N.S.K.); Erasmus University Medical Center, Rotterdam, the Netherlands (N.M.V.M., P.W.J.C.S., A.P.K.); Beth Israel Deaconess Medical Center, Boston (J.J.P.); the Heart Center, Rigshospitalet, Copenhagen (L.S., P.S.O.); PinnacleHealth Hospitals, Harrisburg (M.M., H.G.), and University of Pittsburgh Medical Center, Pittsburgh (T.G., J.S.L.) - both in Pennsylvania; Mount Sinai Health System (D.H.A.) and New York University Langone Medical Center (M.W.) - both in New York; University of Michigan, Ann Arbor (G.M.D., S.C.), and Spectrum Health Hospitals, Grand Rapids (J.H., W.M.) - both in Michigan; Tenet Healthcare, Delray Beach, FL (B.M.); German Heart Center Munich, Munich (R.L.), and Siegburg Heart Center, Siegburg (E.G.) - both in Germany; Mayo Clinic, Rochester (J.K.O.), Medtronic, Minneapolis (E.V., H.N., Y.C.), and Paradigm Biostatistics, Anoka (A.S.M.) - all in Minnesota; McGill University Medical Centre, Montreal (N.P.); University Hospital Bern, Bern, Switzerland (S.W.); Riverside Methodist Hospital, Columbus, OH (S.J.Y.); Cedars-Sinai Medical Center, Los Angeles (R.M.); and Johns Hopkins University, Baltimore (J.C.)
| | - Mathew Williams
- From Methodist DeBakey Heart and Vascular Center, Houston (M.J.R., N.S.K.); Erasmus University Medical Center, Rotterdam, the Netherlands (N.M.V.M., P.W.J.C.S., A.P.K.); Beth Israel Deaconess Medical Center, Boston (J.J.P.); the Heart Center, Rigshospitalet, Copenhagen (L.S., P.S.O.); PinnacleHealth Hospitals, Harrisburg (M.M., H.G.), and University of Pittsburgh Medical Center, Pittsburgh (T.G., J.S.L.) - both in Pennsylvania; Mount Sinai Health System (D.H.A.) and New York University Langone Medical Center (M.W.) - both in New York; University of Michigan, Ann Arbor (G.M.D., S.C.), and Spectrum Health Hospitals, Grand Rapids (J.H., W.M.) - both in Michigan; Tenet Healthcare, Delray Beach, FL (B.M.); German Heart Center Munich, Munich (R.L.), and Siegburg Heart Center, Siegburg (E.G.) - both in Germany; Mayo Clinic, Rochester (J.K.O.), Medtronic, Minneapolis (E.V., H.N., Y.C.), and Paradigm Biostatistics, Anoka (A.S.M.) - all in Minnesota; McGill University Medical Centre, Montreal (N.P.); University Hospital Bern, Bern, Switzerland (S.W.); Riverside Methodist Hospital, Columbus, OH (S.J.Y.); Cedars-Sinai Medical Center, Los Angeles (R.M.); and Johns Hopkins University, Baltimore (J.C.)
| | - Stephan Windecker
- From Methodist DeBakey Heart and Vascular Center, Houston (M.J.R., N.S.K.); Erasmus University Medical Center, Rotterdam, the Netherlands (N.M.V.M., P.W.J.C.S., A.P.K.); Beth Israel Deaconess Medical Center, Boston (J.J.P.); the Heart Center, Rigshospitalet, Copenhagen (L.S., P.S.O.); PinnacleHealth Hospitals, Harrisburg (M.M., H.G.), and University of Pittsburgh Medical Center, Pittsburgh (T.G., J.S.L.) - both in Pennsylvania; Mount Sinai Health System (D.H.A.) and New York University Langone Medical Center (M.W.) - both in New York; University of Michigan, Ann Arbor (G.M.D., S.C.), and Spectrum Health Hospitals, Grand Rapids (J.H., W.M.) - both in Michigan; Tenet Healthcare, Delray Beach, FL (B.M.); German Heart Center Munich, Munich (R.L.), and Siegburg Heart Center, Siegburg (E.G.) - both in Germany; Mayo Clinic, Rochester (J.K.O.), Medtronic, Minneapolis (E.V., H.N., Y.C.), and Paradigm Biostatistics, Anoka (A.S.M.) - all in Minnesota; McGill University Medical Centre, Montreal (N.P.); University Hospital Bern, Bern, Switzerland (S.W.); Riverside Methodist Hospital, Columbus, OH (S.J.Y.); Cedars-Sinai Medical Center, Los Angeles (R.M.); and Johns Hopkins University, Baltimore (J.C.)
| | - Steven J Yakubov
- From Methodist DeBakey Heart and Vascular Center, Houston (M.J.R., N.S.K.); Erasmus University Medical Center, Rotterdam, the Netherlands (N.M.V.M., P.W.J.C.S., A.P.K.); Beth Israel Deaconess Medical Center, Boston (J.J.P.); the Heart Center, Rigshospitalet, Copenhagen (L.S., P.S.O.); PinnacleHealth Hospitals, Harrisburg (M.M., H.G.), and University of Pittsburgh Medical Center, Pittsburgh (T.G., J.S.L.) - both in Pennsylvania; Mount Sinai Health System (D.H.A.) and New York University Langone Medical Center (M.W.) - both in New York; University of Michigan, Ann Arbor (G.M.D., S.C.), and Spectrum Health Hospitals, Grand Rapids (J.H., W.M.) - both in Michigan; Tenet Healthcare, Delray Beach, FL (B.M.); German Heart Center Munich, Munich (R.L.), and Siegburg Heart Center, Siegburg (E.G.) - both in Germany; Mayo Clinic, Rochester (J.K.O.), Medtronic, Minneapolis (E.V., H.N., Y.C.), and Paradigm Biostatistics, Anoka (A.S.M.) - all in Minnesota; McGill University Medical Centre, Montreal (N.P.); University Hospital Bern, Bern, Switzerland (S.W.); Riverside Methodist Hospital, Columbus, OH (S.J.Y.); Cedars-Sinai Medical Center, Los Angeles (R.M.); and Johns Hopkins University, Baltimore (J.C.)
| | - Eberhard Grube
- From Methodist DeBakey Heart and Vascular Center, Houston (M.J.R., N.S.K.); Erasmus University Medical Center, Rotterdam, the Netherlands (N.M.V.M., P.W.J.C.S., A.P.K.); Beth Israel Deaconess Medical Center, Boston (J.J.P.); the Heart Center, Rigshospitalet, Copenhagen (L.S., P.S.O.); PinnacleHealth Hospitals, Harrisburg (M.M., H.G.), and University of Pittsburgh Medical Center, Pittsburgh (T.G., J.S.L.) - both in Pennsylvania; Mount Sinai Health System (D.H.A.) and New York University Langone Medical Center (M.W.) - both in New York; University of Michigan, Ann Arbor (G.M.D., S.C.), and Spectrum Health Hospitals, Grand Rapids (J.H., W.M.) - both in Michigan; Tenet Healthcare, Delray Beach, FL (B.M.); German Heart Center Munich, Munich (R.L.), and Siegburg Heart Center, Siegburg (E.G.) - both in Germany; Mayo Clinic, Rochester (J.K.O.), Medtronic, Minneapolis (E.V., H.N., Y.C.), and Paradigm Biostatistics, Anoka (A.S.M.) - all in Minnesota; McGill University Medical Centre, Montreal (N.P.); University Hospital Bern, Bern, Switzerland (S.W.); Riverside Methodist Hospital, Columbus, OH (S.J.Y.); Cedars-Sinai Medical Center, Los Angeles (R.M.); and Johns Hopkins University, Baltimore (J.C.)
| | - Raj Makkar
- From Methodist DeBakey Heart and Vascular Center, Houston (M.J.R., N.S.K.); Erasmus University Medical Center, Rotterdam, the Netherlands (N.M.V.M., P.W.J.C.S., A.P.K.); Beth Israel Deaconess Medical Center, Boston (J.J.P.); the Heart Center, Rigshospitalet, Copenhagen (L.S., P.S.O.); PinnacleHealth Hospitals, Harrisburg (M.M., H.G.), and University of Pittsburgh Medical Center, Pittsburgh (T.G., J.S.L.) - both in Pennsylvania; Mount Sinai Health System (D.H.A.) and New York University Langone Medical Center (M.W.) - both in New York; University of Michigan, Ann Arbor (G.M.D., S.C.), and Spectrum Health Hospitals, Grand Rapids (J.H., W.M.) - both in Michigan; Tenet Healthcare, Delray Beach, FL (B.M.); German Heart Center Munich, Munich (R.L.), and Siegburg Heart Center, Siegburg (E.G.) - both in Germany; Mayo Clinic, Rochester (J.K.O.), Medtronic, Minneapolis (E.V., H.N., Y.C.), and Paradigm Biostatistics, Anoka (A.S.M.) - all in Minnesota; McGill University Medical Centre, Montreal (N.P.); University Hospital Bern, Bern, Switzerland (S.W.); Riverside Methodist Hospital, Columbus, OH (S.J.Y.); Cedars-Sinai Medical Center, Los Angeles (R.M.); and Johns Hopkins University, Baltimore (J.C.)
| | - Joon S Lee
- From Methodist DeBakey Heart and Vascular Center, Houston (M.J.R., N.S.K.); Erasmus University Medical Center, Rotterdam, the Netherlands (N.M.V.M., P.W.J.C.S., A.P.K.); Beth Israel Deaconess Medical Center, Boston (J.J.P.); the Heart Center, Rigshospitalet, Copenhagen (L.S., P.S.O.); PinnacleHealth Hospitals, Harrisburg (M.M., H.G.), and University of Pittsburgh Medical Center, Pittsburgh (T.G., J.S.L.) - both in Pennsylvania; Mount Sinai Health System (D.H.A.) and New York University Langone Medical Center (M.W.) - both in New York; University of Michigan, Ann Arbor (G.M.D., S.C.), and Spectrum Health Hospitals, Grand Rapids (J.H., W.M.) - both in Michigan; Tenet Healthcare, Delray Beach, FL (B.M.); German Heart Center Munich, Munich (R.L.), and Siegburg Heart Center, Siegburg (E.G.) - both in Germany; Mayo Clinic, Rochester (J.K.O.), Medtronic, Minneapolis (E.V., H.N., Y.C.), and Paradigm Biostatistics, Anoka (A.S.M.) - all in Minnesota; McGill University Medical Centre, Montreal (N.P.); University Hospital Bern, Bern, Switzerland (S.W.); Riverside Methodist Hospital, Columbus, OH (S.J.Y.); Cedars-Sinai Medical Center, Los Angeles (R.M.); and Johns Hopkins University, Baltimore (J.C.)
| | - John Conte
- From Methodist DeBakey Heart and Vascular Center, Houston (M.J.R., N.S.K.); Erasmus University Medical Center, Rotterdam, the Netherlands (N.M.V.M., P.W.J.C.S., A.P.K.); Beth Israel Deaconess Medical Center, Boston (J.J.P.); the Heart Center, Rigshospitalet, Copenhagen (L.S., P.S.O.); PinnacleHealth Hospitals, Harrisburg (M.M., H.G.), and University of Pittsburgh Medical Center, Pittsburgh (T.G., J.S.L.) - both in Pennsylvania; Mount Sinai Health System (D.H.A.) and New York University Langone Medical Center (M.W.) - both in New York; University of Michigan, Ann Arbor (G.M.D., S.C.), and Spectrum Health Hospitals, Grand Rapids (J.H., W.M.) - both in Michigan; Tenet Healthcare, Delray Beach, FL (B.M.); German Heart Center Munich, Munich (R.L.), and Siegburg Heart Center, Siegburg (E.G.) - both in Germany; Mayo Clinic, Rochester (J.K.O.), Medtronic, Minneapolis (E.V., H.N., Y.C.), and Paradigm Biostatistics, Anoka (A.S.M.) - all in Minnesota; McGill University Medical Centre, Montreal (N.P.); University Hospital Bern, Bern, Switzerland (S.W.); Riverside Methodist Hospital, Columbus, OH (S.J.Y.); Cedars-Sinai Medical Center, Los Angeles (R.M.); and Johns Hopkins University, Baltimore (J.C.)
| | - Eric Vang
- From Methodist DeBakey Heart and Vascular Center, Houston (M.J.R., N.S.K.); Erasmus University Medical Center, Rotterdam, the Netherlands (N.M.V.M., P.W.J.C.S., A.P.K.); Beth Israel Deaconess Medical Center, Boston (J.J.P.); the Heart Center, Rigshospitalet, Copenhagen (L.S., P.S.O.); PinnacleHealth Hospitals, Harrisburg (M.M., H.G.), and University of Pittsburgh Medical Center, Pittsburgh (T.G., J.S.L.) - both in Pennsylvania; Mount Sinai Health System (D.H.A.) and New York University Langone Medical Center (M.W.) - both in New York; University of Michigan, Ann Arbor (G.M.D., S.C.), and Spectrum Health Hospitals, Grand Rapids (J.H., W.M.) - both in Michigan; Tenet Healthcare, Delray Beach, FL (B.M.); German Heart Center Munich, Munich (R.L.), and Siegburg Heart Center, Siegburg (E.G.) - both in Germany; Mayo Clinic, Rochester (J.K.O.), Medtronic, Minneapolis (E.V., H.N., Y.C.), and Paradigm Biostatistics, Anoka (A.S.M.) - all in Minnesota; McGill University Medical Centre, Montreal (N.P.); University Hospital Bern, Bern, Switzerland (S.W.); Riverside Methodist Hospital, Columbus, OH (S.J.Y.); Cedars-Sinai Medical Center, Los Angeles (R.M.); and Johns Hopkins University, Baltimore (J.C.)
| | - Hang Nguyen
- From Methodist DeBakey Heart and Vascular Center, Houston (M.J.R., N.S.K.); Erasmus University Medical Center, Rotterdam, the Netherlands (N.M.V.M., P.W.J.C.S., A.P.K.); Beth Israel Deaconess Medical Center, Boston (J.J.P.); the Heart Center, Rigshospitalet, Copenhagen (L.S., P.S.O.); PinnacleHealth Hospitals, Harrisburg (M.M., H.G.), and University of Pittsburgh Medical Center, Pittsburgh (T.G., J.S.L.) - both in Pennsylvania; Mount Sinai Health System (D.H.A.) and New York University Langone Medical Center (M.W.) - both in New York; University of Michigan, Ann Arbor (G.M.D., S.C.), and Spectrum Health Hospitals, Grand Rapids (J.H., W.M.) - both in Michigan; Tenet Healthcare, Delray Beach, FL (B.M.); German Heart Center Munich, Munich (R.L.), and Siegburg Heart Center, Siegburg (E.G.) - both in Germany; Mayo Clinic, Rochester (J.K.O.), Medtronic, Minneapolis (E.V., H.N., Y.C.), and Paradigm Biostatistics, Anoka (A.S.M.) - all in Minnesota; McGill University Medical Centre, Montreal (N.P.); University Hospital Bern, Bern, Switzerland (S.W.); Riverside Methodist Hospital, Columbus, OH (S.J.Y.); Cedars-Sinai Medical Center, Los Angeles (R.M.); and Johns Hopkins University, Baltimore (J.C.)
| | - Yanping Chang
- From Methodist DeBakey Heart and Vascular Center, Houston (M.J.R., N.S.K.); Erasmus University Medical Center, Rotterdam, the Netherlands (N.M.V.M., P.W.J.C.S., A.P.K.); Beth Israel Deaconess Medical Center, Boston (J.J.P.); the Heart Center, Rigshospitalet, Copenhagen (L.S., P.S.O.); PinnacleHealth Hospitals, Harrisburg (M.M., H.G.), and University of Pittsburgh Medical Center, Pittsburgh (T.G., J.S.L.) - both in Pennsylvania; Mount Sinai Health System (D.H.A.) and New York University Langone Medical Center (M.W.) - both in New York; University of Michigan, Ann Arbor (G.M.D., S.C.), and Spectrum Health Hospitals, Grand Rapids (J.H., W.M.) - both in Michigan; Tenet Healthcare, Delray Beach, FL (B.M.); German Heart Center Munich, Munich (R.L.), and Siegburg Heart Center, Siegburg (E.G.) - both in Germany; Mayo Clinic, Rochester (J.K.O.), Medtronic, Minneapolis (E.V., H.N., Y.C.), and Paradigm Biostatistics, Anoka (A.S.M.) - all in Minnesota; McGill University Medical Centre, Montreal (N.P.); University Hospital Bern, Bern, Switzerland (S.W.); Riverside Methodist Hospital, Columbus, OH (S.J.Y.); Cedars-Sinai Medical Center, Los Angeles (R.M.); and Johns Hopkins University, Baltimore (J.C.)
| | - Andrew S Mugglin
- From Methodist DeBakey Heart and Vascular Center, Houston (M.J.R., N.S.K.); Erasmus University Medical Center, Rotterdam, the Netherlands (N.M.V.M., P.W.J.C.S., A.P.K.); Beth Israel Deaconess Medical Center, Boston (J.J.P.); the Heart Center, Rigshospitalet, Copenhagen (L.S., P.S.O.); PinnacleHealth Hospitals, Harrisburg (M.M., H.G.), and University of Pittsburgh Medical Center, Pittsburgh (T.G., J.S.L.) - both in Pennsylvania; Mount Sinai Health System (D.H.A.) and New York University Langone Medical Center (M.W.) - both in New York; University of Michigan, Ann Arbor (G.M.D., S.C.), and Spectrum Health Hospitals, Grand Rapids (J.H., W.M.) - both in Michigan; Tenet Healthcare, Delray Beach, FL (B.M.); German Heart Center Munich, Munich (R.L.), and Siegburg Heart Center, Siegburg (E.G.) - both in Germany; Mayo Clinic, Rochester (J.K.O.), Medtronic, Minneapolis (E.V., H.N., Y.C.), and Paradigm Biostatistics, Anoka (A.S.M.) - all in Minnesota; McGill University Medical Centre, Montreal (N.P.); University Hospital Bern, Bern, Switzerland (S.W.); Riverside Methodist Hospital, Columbus, OH (S.J.Y.); Cedars-Sinai Medical Center, Los Angeles (R.M.); and Johns Hopkins University, Baltimore (J.C.)
| | - Patrick W J C Serruys
- From Methodist DeBakey Heart and Vascular Center, Houston (M.J.R., N.S.K.); Erasmus University Medical Center, Rotterdam, the Netherlands (N.M.V.M., P.W.J.C.S., A.P.K.); Beth Israel Deaconess Medical Center, Boston (J.J.P.); the Heart Center, Rigshospitalet, Copenhagen (L.S., P.S.O.); PinnacleHealth Hospitals, Harrisburg (M.M., H.G.), and University of Pittsburgh Medical Center, Pittsburgh (T.G., J.S.L.) - both in Pennsylvania; Mount Sinai Health System (D.H.A.) and New York University Langone Medical Center (M.W.) - both in New York; University of Michigan, Ann Arbor (G.M.D., S.C.), and Spectrum Health Hospitals, Grand Rapids (J.H., W.M.) - both in Michigan; Tenet Healthcare, Delray Beach, FL (B.M.); German Heart Center Munich, Munich (R.L.), and Siegburg Heart Center, Siegburg (E.G.) - both in Germany; Mayo Clinic, Rochester (J.K.O.), Medtronic, Minneapolis (E.V., H.N., Y.C.), and Paradigm Biostatistics, Anoka (A.S.M.) - all in Minnesota; McGill University Medical Centre, Montreal (N.P.); University Hospital Bern, Bern, Switzerland (S.W.); Riverside Methodist Hospital, Columbus, OH (S.J.Y.); Cedars-Sinai Medical Center, Los Angeles (R.M.); and Johns Hopkins University, Baltimore (J.C.)
| | - Arie P Kappetein
- From Methodist DeBakey Heart and Vascular Center, Houston (M.J.R., N.S.K.); Erasmus University Medical Center, Rotterdam, the Netherlands (N.M.V.M., P.W.J.C.S., A.P.K.); Beth Israel Deaconess Medical Center, Boston (J.J.P.); the Heart Center, Rigshospitalet, Copenhagen (L.S., P.S.O.); PinnacleHealth Hospitals, Harrisburg (M.M., H.G.), and University of Pittsburgh Medical Center, Pittsburgh (T.G., J.S.L.) - both in Pennsylvania; Mount Sinai Health System (D.H.A.) and New York University Langone Medical Center (M.W.) - both in New York; University of Michigan, Ann Arbor (G.M.D., S.C.), and Spectrum Health Hospitals, Grand Rapids (J.H., W.M.) - both in Michigan; Tenet Healthcare, Delray Beach, FL (B.M.); German Heart Center Munich, Munich (R.L.), and Siegburg Heart Center, Siegburg (E.G.) - both in Germany; Mayo Clinic, Rochester (J.K.O.), Medtronic, Minneapolis (E.V., H.N., Y.C.), and Paradigm Biostatistics, Anoka (A.S.M.) - all in Minnesota; McGill University Medical Centre, Montreal (N.P.); University Hospital Bern, Bern, Switzerland (S.W.); Riverside Methodist Hospital, Columbus, OH (S.J.Y.); Cedars-Sinai Medical Center, Los Angeles (R.M.); and Johns Hopkins University, Baltimore (J.C.)
| |
Collapse
|
231
|
Abstract
Older adults make up an ever-increasing number of patients presenting for surgery, and a significant percentage of these patients will be frail. Frailty is a geriatric syndrome that has been conceptualized as decreased reserve when confronted with stressors, although the precise definition of frailty has not been easy to standardize. The 2 most popular approaches to define frailty are the phenotypic approach and the deficit accumulation approach, although at least 20 tools have been developed, which has made comparison across studies difficult. In epidemiologic studies, baseline frailty has been associated with poor outcomes in both community cohorts and hospitalized patients. Specifically in cardiac surgery (including transcatheter aortic valve implantation procedures), frailty has been strongly associated with postoperative mortality and morbidity, and thus frailty likely improves the identification of high-risk patients beyond known risk scores. For perioperative physicians then, the question arises of how to incorporate this information into perioperative care. To date, 2 thrusts of research and clinical practice have emerged: (1) preoperative identification of high-risk patients to guide both patient expectations and surgical decision-making; and (2) perioperative optimization strategies for frail patients. However, despite the strong association of frailty and poor outcomes, there is a lack of well-designed trials that have examined perioperative interventions with a specific focus on frail patients undergoing cardiac surgery. Thus, in many cases, principles of geriatric care may need to be applied. Further research is needed to standardize and implement the feasible definitions of frailty and examine perioperative interventions for frail patients undergoing cardiac surgery.
Collapse
Affiliation(s)
- Antonio Graham
- From the *Division of Geriatric Medicine and Gerontology, Johns Hopkins University School of Medicine, Baltimore, Maryland; and †Department of Anesthesiology and Critical Care Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland
| | | |
Collapse
|
232
|
González-Ferreiro R, Muñoz-García AJ, López-Otero D, Avanzas P, Pascual I, Alonso-Briales JH, Trillo-Nouche R, Pun F, Jiménez-Navarro MF, Hernández-García JM, Morís C, González Juanatey JR. Prognostic value of body mass index in transcatheter aortic valve implantation: A “J”-shaped curve. Int J Cardiol 2017; 232:342-347. [DOI: 10.1016/j.ijcard.2016.12.051] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/14/2016] [Revised: 11/10/2016] [Accepted: 12/16/2016] [Indexed: 12/11/2022]
|
233
|
Cocchia R, D'Andrea A, Conte M, Cavallaro M, Riegler L, Citro R, Sirignano C, Imbriaco M, Cappelli M, Gregorio G, Calabrò R, Bossone E. Patient selection for transcatheter aortic valve replacement: A combined clinical and multimodality imaging approach. World J Cardiol 2017; 9:212-229. [PMID: 28400918 PMCID: PMC5368671 DOI: 10.4330/wjc.v9.i3.212] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/27/2016] [Revised: 12/15/2016] [Accepted: 01/11/2017] [Indexed: 02/06/2023] Open
Abstract
Transcatheter aortic valve replacement (TAVR) has been validated as a new therapy for patients affected by severe symptomatic aortic stenosis who are not eligible for surgical intervention because of major contraindication or high operative risk. Patient selection for TAVR should be based not only on accurate assessment of aortic stenosis morphology, but also on several clinical and functional data. Multi-Imaging modalities should be preferred for assessing the anatomy and the dimensions of the aortic valve and annulus before TAVR. Ultrasounds represent the first line tool in evaluation of this patients giving detailed anatomic description of aortic valve complex and allowing estimating with enough reliability the hemodynamic entity of valvular stenosis. Angiography should be used to assess coronary involvement and plan a revascularization strategy before the implant. Multislice computed tomography play a central role as it can give anatomical details in order to choice the best fitting prosthesis, evaluate the morphology of the access path and detect other relevant comorbidities. Cardiovascular magnetic resonance and positron emission tomography are emergent modality helpful in aortic stenosis evaluation. The aim of this review is to give an overview on TAVR clinical and technical aspects essential for adequate selection.
Collapse
Affiliation(s)
- Rosangela Cocchia
- Rosangela Cocchia, Rodolfo Citro, Eduardo Bossone, Department of Cardiology and Cardiac Surgery, San Giovanni di Dio Hospital, 00733 Salern, Italy
| | - Antonello D'Andrea
- Rosangela Cocchia, Rodolfo Citro, Eduardo Bossone, Department of Cardiology and Cardiac Surgery, San Giovanni di Dio Hospital, 00733 Salern, Italy
| | - Marianna Conte
- Rosangela Cocchia, Rodolfo Citro, Eduardo Bossone, Department of Cardiology and Cardiac Surgery, San Giovanni di Dio Hospital, 00733 Salern, Italy
| | - Massimo Cavallaro
- Rosangela Cocchia, Rodolfo Citro, Eduardo Bossone, Department of Cardiology and Cardiac Surgery, San Giovanni di Dio Hospital, 00733 Salern, Italy
| | - Lucia Riegler
- Rosangela Cocchia, Rodolfo Citro, Eduardo Bossone, Department of Cardiology and Cardiac Surgery, San Giovanni di Dio Hospital, 00733 Salern, Italy
| | - Rodolfo Citro
- Rosangela Cocchia, Rodolfo Citro, Eduardo Bossone, Department of Cardiology and Cardiac Surgery, San Giovanni di Dio Hospital, 00733 Salern, Italy
| | - Cesare Sirignano
- Rosangela Cocchia, Rodolfo Citro, Eduardo Bossone, Department of Cardiology and Cardiac Surgery, San Giovanni di Dio Hospital, 00733 Salern, Italy
| | - Massimo Imbriaco
- Rosangela Cocchia, Rodolfo Citro, Eduardo Bossone, Department of Cardiology and Cardiac Surgery, San Giovanni di Dio Hospital, 00733 Salern, Italy
| | - Maurizio Cappelli
- Rosangela Cocchia, Rodolfo Citro, Eduardo Bossone, Department of Cardiology and Cardiac Surgery, San Giovanni di Dio Hospital, 00733 Salern, Italy
| | - Giovanni Gregorio
- Rosangela Cocchia, Rodolfo Citro, Eduardo Bossone, Department of Cardiology and Cardiac Surgery, San Giovanni di Dio Hospital, 00733 Salern, Italy
| | - Raffaele Calabrò
- Rosangela Cocchia, Rodolfo Citro, Eduardo Bossone, Department of Cardiology and Cardiac Surgery, San Giovanni di Dio Hospital, 00733 Salern, Italy
| | - Eduardo Bossone
- Rosangela Cocchia, Rodolfo Citro, Eduardo Bossone, Department of Cardiology and Cardiac Surgery, San Giovanni di Dio Hospital, 00733 Salern, Italy
| |
Collapse
|
234
|
Prognostic Value of Hypoalbuminemia After Transcatheter Aortic Valve Implantation (from the Japanese Multicenter OCEAN-TAVI Registry). Am J Cardiol 2017; 119:770-777. [PMID: 28017301 DOI: 10.1016/j.amjcard.2016.11.019] [Citation(s) in RCA: 56] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/31/2016] [Revised: 11/03/2016] [Accepted: 11/03/2016] [Indexed: 11/23/2022]
Abstract
Hypoalbuminemia, a frailty criterion, belongs to a group of co-morbidities not captured as a traditional risk factor. We assessed its prognostic value in patients who underwent transcatheter aortic valve implantation (TAVI). The study included 1,215 consecutive patients from the Optimized Catheter Valvular Intervention -TAVI Japanese multicenter registry. Hypoalbuminemia was defined as serum albumin level <3.5 g/dl. Baseline characteristics, procedural outcomes, and all-cause, cardiovascular and noncardiovascular mortality rates after TAVI were compared between patients with albumin level <3.5 g/dl (hypo[h]-ALB group, n = 284) and those with albumin level >3.5 g/dl (nonhypo[nh]-ALB group, n = 931). Several baseline characteristics differed significantly between both groups, including age (85.1 ± 5.1 vs 84.2 ± 4.9 years, p = 0.012), ejection fraction (58.5 ± 14.3% vs 62.9 ± 12.4%, p <0.001), baseline kidney function, or liver disease. The 30-day mortality rate in all patients showed significant differences between the 2 groups (3.9% vs 1.3%, p = 0.005). During a mean follow-up of 330 days, cumulative all-cause, cardiovascular, and noncardiovascular mortality rates were significantly higher in the hALB group than in the nhALB group (log-rank test, p <0.001, p = 0.0021, and p <0.001, respectively). The groups were also analyzed using a propensity matching model for adjusting the baseline differences. The analysis revealed that the poorer prognosis of the hALB group in terms of cumulative all-cause and noncardiovascular mortality was retained (p = 0.038, and p = 0.0068, respectively); however, differences in cardiovascular mortality rates in the 2 groups were attenuated (p = 0.93). In conclusion, hypoalbuminemia was associated with poor prognosis, highlighted by the increase in noncardiovascular mortality. Baseline albumin level could be a useful marker for risk stratification before TAVI.
Collapse
|
235
|
Thongprayoon C, Cheungpasitporn W, Kashani K. The impact of frailty on mortality after transcatheter aortic valve replacement. ANNALS OF TRANSLATIONAL MEDICINE 2017; 5:144. [PMID: 28462224 DOI: 10.21037/atm.2017.01.35] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
Frailty is a notably common problem in patients with severe aortic stenosis (AS) undergoing transcatheter aortic valve replacement (TAVR) evaluation. Studies have demonstrated significant associations between frailty and worse outcomes in patients undergoing TAVR including higher risks of disability and mortality and admissions to long-term care facility. While there are multiple methods to identify and measure frailty, there is a critical need for a precise definition of frailty and its standardized assessment protocol based on well-established tests covering all aspects of the frailty, as a syndrome. Incorporation of the available frailty evaluation into pre-operative risk assessments chances of morbidity or mortality following surgery can help enhancing performance and improve shared decision-making between physicians and their patients. In this review, we present the perspectives of the impact of frailty on mortality in patients undergoing TAVR.
Collapse
Affiliation(s)
- Charat Thongprayoon
- Division of Nephrology and Hypertension, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.,Department of Internal Medicine, Bassett Medical Center, Cooperstown, NY, USA
| | - Wisit Cheungpasitporn
- Division of Nephrology and Hypertension, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA
| | - Kianoush Kashani
- Division of Nephrology and Hypertension, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.,Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA
| |
Collapse
|
236
|
Kleczynski P, Dziewierz A, Bagienski M, Rzeszutko L, Sorysz D, Trebacz J, Sobczynski R, Tomala M, Stapor M, Dudek D. Impact of frailty on mortality after transcatheter aortic valve implantation. Am Heart J 2017; 185:52-58. [PMID: 28267475 DOI: 10.1016/j.ahj.2016.12.005] [Citation(s) in RCA: 75] [Impact Index Per Article: 9.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/14/2016] [Accepted: 12/09/2016] [Indexed: 10/20/2022]
Abstract
BACKGROUND We sought to investigate the relation between frailty indices and 12-month mortality after transcatheter aortic valve implantation (TAVI). METHODS We included 101 consecutive patients with severe aortic stenosis who have undergone TAVI. Frailty indices according to Valve Academic Research Consortium-2 recommendations (5-m walk test [5MWT] and hand grip strength) as well as other available scales of frailty (Katz index, Elderly Mobility Scale [EMS], Canadian Study of Health and Aging [CSHA] scale, Identification of Seniors at Risk [ISAR] scale) were assessed at baseline. The primary endpoint was 12-month all-cause mortality. RESULTS Twelve-month all-cause mortality was 17.8%. According to 5MWT, 17.8% were frail; hand grip test: 6.9%; Katz index: 17.8%; EMS: 7.9%; CSHA scale: 16.9%; and ISAR scale: 52.5%. Associations between frailty indices and 12-month all-cause mortality after TAVI were significant in Cox regression analysis (frail vs not frail, presented as hazard ratio[95%CI] adjusted for logistic EuroSCORE): for 5MWT, 72.38 (15.95-328.44); for EMS, 23.39 (6.89-79.34); for CSHA scale, 53.97 (14.67-198.53); for Katz index, 21.69 (6.89-68.25); for hand grip strength, 51.54 (12.98-204.74); and for ISAR scale, 15.94 (2.10-120.74). Similarly, such relationship was confirmed when 5MWT, EMS, and CSHA were used as continuous variables (hazard ratio [95%CI] adjusted for logistic EuroSCORE: for 5MWT per 1-second increase, 2.55 [1.94-3.37]; for EMS per 1-point decrease, 2.90 (1.99-4.21); and for CSHA per 1-point increase, 3.13 [2.17-4.53]). CONCLUSIONS Our study confirmed a strong predictive ability of most of the proposed frailty indices for 12-month mortality after TAVI. For patients scheduled for TAVI, the use of frailty indices, which are easy and quick to assess on clinical basis but with strong performance, for example, 5MWT, EMS, or hand grip test, may be advocated.
Collapse
|
237
|
Marshall L, Griffin R, Mundy J. Frailty assessment to predict short term outcomes after cardiac surgery. Asian Cardiovasc Thorac Ann 2017; 24:546-54. [PMID: 27329115 DOI: 10.1177/0218492316653557] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
Abstract
BACKGROUND Frailty has been used to predict outcome in gerontology but has only recently been applied to measures of perioperative risk stratification. It provides information on physiological reserve not addressed by current scoring systems which are heavily reliant on age. METHODS We enrolled 123 patients over 70-years old (mean age 77.1 years, 69% male) undergoing open cardiac surgery, and assessed in 11 different frailty measures. These were combined into a cumulative score that was stratified into robust (49%), borderline (37%), and frail (14%) groups. The groups were compared for a short-term composite measure comprising mortality, deep sternal wound infection, inter-facility discharge or prolonged length of stay, as well as 3-month mortality and quality of life and 6-month mortality. RESULTS Frail patients had a considerably higher incidence of an unfavorable composite outcome (52.9%) compared to their borderline (28.3%) and robust (13.3%) counterparts (p = 0.003). Hospital mortality was 4/123 (3.3%) with a further 3 within 30 days, and 2 late deaths occurred within 6 months postoperatively. This was statistically significant with greater mortality at 6 months in the frail cohort. Quality of life at 3 months showed a trend towards greater improvement in the borderline patients compared to either the robust or frail groups. DISCUSSION Frailty status impacts on both short- and intermediate-term outcomes, including postoperative quality of life. In an ageing population where nonmaleficence and resource allocation are increasingly important, individual assessment in marginal surgical candidates may provide additional information to both the patient and clinician.
Collapse
Affiliation(s)
- Lachlan Marshall
- Department of Cardiothoracic Surgery, Princess Alexandra Hospital Woolloongabba, Queensland, Australia
| | - Rayleene Griffin
- Department of Cardiothoracic Surgery, Princess Alexandra Hospital Woolloongabba, Queensland, Australia
| | - Julie Mundy
- Department of Cardiothoracic Surgery, Princess Alexandra Hospital Woolloongabba, Queensland, Australia
| |
Collapse
|
238
|
Talbot-Hamon C, Afilalo J. Transcatheter Aortic Valve Replacement in the Care of Older Persons with Aortic Stenosis. J Am Geriatr Soc 2017; 65:693-698. [DOI: 10.1111/jgs.14776] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Affiliation(s)
- Catherine Talbot-Hamon
- Division of Geriatric Medicine; McGill University; Montreal Quebec
- Department of Epidemiology, Biostatistics, and Occupational Health; McGill University; Montreal Quebec
| | - Jonathan Afilalo
- Division of Cardiology; Jewish General Hospital; McGill University; Montreal Quebec
- Department of Epidemiology, Biostatistics, and Occupational Health; McGill University; Montreal Quebec
| |
Collapse
|
239
|
Tarro Genta F, Tidu M, Bouslenko Z, Bertolin F, Salvetti I, Comazzi F, Giannuzzi P. Cardiac rehabilitation after transcatheter aortic valve implantation compared to patients after valve replacement. J Cardiovasc Med (Hagerstown) 2017; 18:114-120. [DOI: 10.2459/jcm.0000000000000494] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
240
|
Psoas Muscle Area as a Predictor of Outcomes in Transcatheter Aortic Valve Implantation. Am J Cardiol 2017; 119:457-460. [PMID: 27931723 DOI: 10.1016/j.amjcard.2016.10.019] [Citation(s) in RCA: 52] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/17/2016] [Revised: 10/10/2016] [Accepted: 10/10/2016] [Indexed: 11/20/2022]
Abstract
Frailty is a powerful predictor of outcomes after transcatheter aortic valve implantation (TAVI). Sarcopenia as assessed by psoas muscle area (PMA) is a validated tool to assess frailty before surgical procedures. We evaluated PMA as a predictor of outcomes after TAVI in 152 consecutive patients who underwent this procedure at our institution from 2011 to 2014. Preoperative computed tomography scans were used to measure PMA, which then was indexed to body surface area. Outcomes evaluated included (1) early poor outcome (30 days mortality, stroke, dialysis, and prolonged ventilation), (2) 1-year mortality, and (3) high-resource utilization (length of stay >7 days, discharge to rehabilitation, or readmission within 30 days). Indexed PMA (odds ratio [OR] 3.19, confidence interval [CI] 1.30 to 7.83; p = 0.012) and age (OR 1.92, CI 1.87 to 1.98; p = 0.012) predicted early poor outcome. Society of Thoracic Surgeons score predicted 1-year mortality (hazard ratio 3.07, CI 1.93 to 6.23; p = 0.011). High-resource utilization was observed more frequently in patients with PMA less than the median (73% vs 51%, OR 2.65, CI 1.32 to 5.36; p = 0.006). In conclusion, indexed PMA predicts early poor outcome and high-resource utilization after TAVI.
Collapse
|
241
|
Neupane I, Arora RC, Rudolph JL. Cardiac surgery as a stressor and the response of the vulnerable older adult. Exp Gerontol 2017; 87:168-174. [PMID: 27125757 PMCID: PMC5081280 DOI: 10.1016/j.exger.2016.04.019] [Citation(s) in RCA: 39] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2015] [Revised: 03/30/2016] [Accepted: 04/21/2016] [Indexed: 12/21/2022]
Abstract
In an aging population, recovery and restoration of function are critical to maintaining independence. Over the past 50years, there have been dramatic improvements made in cardiac surgery processes and outcomes that allow for procedures to be performed on an increasingly older population with the goal of improving function. Although improved function is possible, major surgical procedures are associated with substantial stress, which can severely impact outcomes. Past literature has identified that frail patients, who are vulnerable to the stress of surgery, are more likely to have postoperative major adverse cardiac and cerebrovascular events (OR 4.9, 95% confidence interval 1.6, 14.6). The objective of this manuscript is to examine preoperative frailty in biological, psychological, and social domains using cardiac surgery to induce stress. We systematically searched PubMed for keywords including "cardiac surgery, frailty, and aged" in addition to the biological, psychological, and social keywords. In the biological domain, we examine the association of physiological and physical vulnerabilities, as well as, the impact of comorbidities and inflammation on negative surgical outcomes. In the psychological domain, the impact of cognitive impairment, depression, and anxiety as vulnerabilities were examined. In the social domain, social structure, coping, disparities, and addiction as vulnerabilities are described. Importantly, there is substantial overlap in the domains of vulnerability. While frailty research has largely focused on discrete physical vulnerability criteria, a broader definition of frailty demonstrates that vulnerabilities in biological, psychological, and social domains can limit recovery after the stress of cardiac surgery. Identification of vulnerability in these domains can allow better understanding of the risks of cardiac surgery and tailoring of interventions to improve outcomes.
Collapse
Affiliation(s)
- Iva Neupane
- Center of Innovation in Long Term Services and Support, Providence VA Medical Center, Providence, RI, United States; Warren Alpert School of Medicine at Brown University, Providence, RI, United States
| | - Rakesh C Arora
- University of Manitoba, College of Medicine, Department of Surgery, Winnipeg, Manitoba, Canada
| | - James L Rudolph
- Center of Innovation in Long Term Services and Support, Providence VA Medical Center, Providence, RI, United States; Warren Alpert School of Medicine at Brown University, Providence, RI, United States.
| |
Collapse
|
242
|
Pinheiro M, Mancio J, Conceição G, Ferreira W, Carvalho M, Santos A, Vouga L, Gama Ribeiro V, Leite-Moreira A, Falcão-Pires I, Bettencourt N. Frailty Syndrome: Visceral Adipose Tissue and Frailty in Patients with Symptomatic Severe Aortic Stenosis. J Nutr Health Aging 2017; 21:120-128. [PMID: 27999858 DOI: 10.1007/s12603-016-0795-x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
BACKGROUND/OBJECTIVES In patients with severe aortic stenosis (AS), frailty is a clinically relevant measure of increased vulnerability that should be included in the preoperative risk assessment. Bioelectrical impedance analysis (BIA) derived phase angle (PA) reflects cell membrane integrity and function. Few studies are available on the relative contribution of adiposity distribution on frailty, and about the influences of frailty and visceral obesity in PA value. Therefore, we aimed to evaluate associations among frailty, visceral fat depots and PA in patients with symptomatic severe AS. METHODS In a cohort of patients with symptomatic severe AS and preserved ejection fraction, we examined the associations between frailty, visceral fat depots and bioelectrical impedance analysis (BIA) derived phase angle (PA); and between visceral fat and PA. Frailty was defined according the Fried et al. scale criteria and the body fat distribution was determined by multidetector computed tomography and by BIA. RESULTS Of the fifty-five included patients, 26 were frail (47%). Adjusting for age and gender, frailty was associated with indexed epicardial adipose tissue volume (EATVi) (the odds of frailty increased 4.1-fold per additional 100 cm3/m2 of EAT [95% confidence interval (CI) of 1.03 to 16.40, p=0.04] and with PA (OR of 0.50, 95% CI, 0.26 to 0.97, p=0.04), but not with body mass index (BMI), waist circumference (WC), indexed total, visceral and subcutaneous abdominal fat areas (TAFAi, VAFAi and SAFAi) nor with indexed mediastinal adipose tissue volume (MATVi). In an age and gender adjusted linear model, PA was inversely correlated with EATVi (β=-0.008, 95% CI, -0.016 to -0.001, p=0.03), but not with BMI, WC, nor with MATVi, VAFAi, SAFAi and TAFAi. CONCLUSIONS In patients with symptomatic severe AS, EATVi is associated with frailty, independently of age and gender, but not with MAFVi or VAFAi. Moreover, frailty and EATVi are associated with impaired cell membrane integrity and function assessed by PA.
Collapse
Affiliation(s)
- M Pinheiro
- Marília Pinheiro, Faculty of Nutrition and Food Sciences, Portugal, E-mail: , Phone (0351) 918197460
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
243
|
Assmann P, Kievit P, van der Wulp K, Verkroost M, Noyez L, Bor H, Schoon Y. Frailty is associated with delirium and mortality after transcatheter aortic valve implantation. Open Heart 2016; 3:e000478. [PMID: 28008356 PMCID: PMC5174802 DOI: 10.1136/openhrt-2016-000478] [Citation(s) in RCA: 47] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/19/2016] [Revised: 09/18/2016] [Accepted: 10/18/2016] [Indexed: 02/06/2023] Open
Abstract
Objective We hypothesised that frailty assessment is of additional value to predict delirium and mortality after transcatheter aortic valve implantation (TAVI). Methods Observational study in 89 consecutive patients who underwent TAVI. Inclusion from November 2012 to February 2014, follow-up until April 2014. Measurement of the association of variables from frailty assessment and cardiological assessment with delirium and mortality after TAVI, respectively. Results Incidence of delirium after TAVI: 25/89 (28%). Variables from frailty assessment protectively associated with delirium were: Mini Mental State Examination, (OR 0.79; 95% CI 0.65 to 0.96; p=0.02), Instrumental Activities of Daily Living (OR 0.79; 95% CI 0.63 to 0.99; p=0.04) and gait speed (OR 0.05; 95% CI 0.01 to 0.50; p=0.01). Timed Up and Go was predictively associated with delirium (OR 1.14; 95% CI 1.03 to 1.26; p=0.01). From cardiological assessment, pulmonary hypertension was protectively associated with delirium (OR 0.34; 95% CI 0.12 to 0.98; p=0.05). Multivariate logistic analysis: Nagelkerke R2=0.359, Mini Mental State Examination was independently associated with delirium. Incidence of mortality: 11/89 (12%). Variables predictively associated with mortality were: the summary score Frailty Index (HR 1.66, 95% CI 1.06 to 2.60; p=0.03), European System for Cardiac Operative Risk Evaluation (EuroSCORE) II (HR 1.14, 95% CI 1.06 to 1.22; p<0.001) and complications (HR 4.81, 95% CI 1.03 to 22.38; p=0.05). Multivariate Cox proportional hazards analysis: Nagelkerke R2=0.271, Frailty Index and EuroSCORE II were independently associated with mortality. Conclusions Delirium frequently occurs after TAVI. Variables from frailty assessment are associated with delirium and mortality, independent of cardiological assessment. Thus, frailty assessment may have additional value in the prediction of delirium and mortality after TAVI.
Collapse
Affiliation(s)
- Patricia Assmann
- Department of Primary and Elderly Care, Radboud University Medical Centre Nijmegen, The Netherlands; ZZG Care Group, Nijmegen, The Netherlands
| | - Peter Kievit
- Department of Cardiology , Radboud University Medical Centre Nijmegen , The Netherlands
| | - Kees van der Wulp
- Department of Cardiology , Radboud University Medical Centre Nijmegen , The Netherlands
| | - Michel Verkroost
- Department of Cardio-Thoracic Surgery , Radboud University Medical Centre Nijmegen , The Netherlands
| | - Luc Noyez
- Department of Cardio-Thoracic Surgery , Radboud University Medical Centre Nijmegen , The Netherlands
| | - Hans Bor
- Department of Primary and Elderly Care , Radboud University Medical Centre Nijmegen , The Netherlands
| | - Yvonne Schoon
- Department of Geriatrics , Radboud University Medical Centre Nijmegen , The Netherlands
| |
Collapse
|
244
|
Vigorito C, Abreu A, Ambrosetti M, Belardinelli R, Corrà U, Cupples M, Davos CH, Hoefer S, Iliou MC, Schmid JP, Voeller H, Doherty P. Frailty and cardiac rehabilitation: A call to action from the EAPC Cardiac Rehabilitation Section. Eur J Prev Cardiol 2016; 24:577-590. [PMID: 27940954 DOI: 10.1177/2047487316682579] [Citation(s) in RCA: 149] [Impact Index Per Article: 16.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
Abstract
Frailty is a geriatric syndrome characterised by a vulnerability status associated with declining function of multiple physiological systems and loss of physiological reserves. Two main models of frailty have been advanced: the phenotypic model (primary frailty) or deficits accumulation model (secondary frailty), and different instruments have been proposed and validated to measure frailty. However measured, frailty correlates to medical outcomes in the elderly, and has been shown to have prognostic value for patients in different clinical settings, such as in patients with coronary artery disease, after cardiac surgery or transvalvular aortic valve replacement, in patients with chronic heart failure or after left ventricular assist device implantation. The prevalence, clinical and prognostic relevance of frailty in a cardiac rehabilitation setting has not yet been well characterised, despite the increasing frequency of elderly patients in cardiac rehabilitation, where frailty is likely to influence the onset, type and intensity of the exercise training programme and the design of tailored rehabilitative interventions for these patients. Therefore, we need to start looking for frailty in elderly patients entering cardiac rehabilitation programmes and become more familiar with some of the tools to recognise and evaluate the severity of this condition. Furthermore, we need to better understand whether exercise-based cardiac rehabilitation may change the course and the prognosis of frailty in cardiovascular patients.
Collapse
Affiliation(s)
- Carlo Vigorito
- 1 Department of Translational Medical Sciences, University of Naples Federico II, Italy
| | - Ana Abreu
- 2 Cardiology Department Hospital Santa Marta, Centro Hospitalar Lisboa Central, Portugal
| | - Marco Ambrosetti
- 3 Cardiovascular Rehabilitation Unit, Le Terrazze Clinic, Cunardo, Italy
| | | | - Ugo Corrà
- 5 Department of Cardiac Rehabilitation, Salvatore Maugeri Foundation, Veruno, Italy
| | - Margaret Cupples
- 6 Department of General Practice, UKCRC Centre of Excellence for Public Health Research (NI), Northern Ireland, Queens University, Belfast
| | - Constantinos H Davos
- 7 Cardiovascular Research Laboratory, Biomedical Research Foundation Academy of Athens, Greece
| | | | - Marie-Christine Iliou
- 9 Cardiac Rehabilitation Department, Hopital Corentin Celton-Assistance Publique Hôpitaux de Paris, France
| | - Jean-Paul Schmid
- 10 Cardiology Clinic, Tiefenau Hospital and University of Bern, Switzerland
| | - Heinz Voeller
- 11 Center of Rehabilitation Research, University of Potsdam, Germany; Department of Cardiology, Klinic am See, Rudersdorf
| | | |
Collapse
|
245
|
Quantitative increase in frailty is associated with diminished survival after transcatheter aortic valve replacement. Am Heart J 2016; 182:146-154. [PMID: 27914495 DOI: 10.1016/j.ahj.2016.06.028] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/13/2016] [Accepted: 06/08/2016] [Indexed: 12/22/2022]
Abstract
BACKGROUND The purpose of this study is to assess the impact of frailty index comprised of commonly used frailty metrics on outcomes following transcatheter aortic valve replacement (TAVR) outcomes, including mortality, length of stay, and discharge destination. METHODS AND RESULTS Retrospective data collection was performed for 342 consecutive patients who underwent TAVR at a single center from May 15, 2012, to September 17, 2015. Frailty index score was calculated using 15-ft walk test, Katz activities of daily living, preoperative serum albumin, and dominant handgrip strength. Patients were given a frailty score from 0/4 to 4/4, with higher scores indicating greater levels of frailty. There were 27 patients (8%) in 0/4, 82 patients (24%) in 1/4, 129 patients (38%) in 2/4, 73 patients (21%) in 3/4, and 31 patients (9%) in 4/4 frailty group. Multivariate cox, logistic, and linear regression analyses showed that patients with frailty score of 3/4 or 4/4 had increased all-cause mortality (P = .015 and P < .001) and were more likely to be discharged to an acute care facility (P = .083 and P = .001). 4/4 frail patients had increased post-operative length of stay (P = .014) when compared to less frail patients. Individual components of the frailty score were also independent predictors of all-cause mortality. Median survival in 4/4 frail patients was 7 months. CONCLUSIONS Frailty index comprised of commonly used frailty metrics and its components are independent predictors of poor post-TAVR outcomes. There is a stepwise increase in mortality and post-TAVR length of stay with increasing frailty with dismal prognosis in extremely frail patients.
Collapse
|
246
|
Rodríguez-Pascual C, Paredes-Galán E, Ferrero-Martínez AI, Baz-Alonso JA, Durán-Muñoz D, González-Babarro E, Sanmartín M, Parajes T, Torres-Torres I, Piñón-Esteban M, Calvo-Iglesias F, Olcoz-Chiva MT, Rodríguez-Artalejo F. The frailty syndrome and mortality among very old patients with symptomatic severe aortic stenosis under different treatments. Int J Cardiol 2016; 224:125-131. [DOI: 10.1016/j.ijcard.2016.09.020] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/19/2016] [Revised: 08/20/2016] [Accepted: 09/12/2016] [Indexed: 12/28/2022]
|
247
|
Pressler A, Christle JW, Lechner B, Grabs V, Haller B, Hettich I, Jochheim D, Mehilli J, Lange R, Bleiziffer S, Halle M. Exercise training improves exercise capacity and quality of life after transcatheter aortic valve implantation: A randomized pilot trial. Am Heart J 2016; 182:44-53. [PMID: 27914499 DOI: 10.1016/j.ahj.2016.08.007] [Citation(s) in RCA: 49] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/16/2016] [Accepted: 08/21/2016] [Indexed: 01/18/2023]
Abstract
BACKGROUND Transcatheter aortic valve implantation (TAVI) is increasingly applied for aortic stenosis in elderly patients with impaired mobility and reduced quality of life. These patients may particularly benefit from postinterventional exercise programs, but no randomized study has evaluated the safety and efficacy of exercise in this population. METHODS In a prospective pilot study, 30 patients after TAVI (mean age, 81±6 years, 44% female, 83±34 days postintervention) were randomly allocated 1:1 to a training group (TG) performing 8 weeks of supervised combined endurance and resistance exercise or to usual care. The formal primary efficacy end point was between-group difference in change in peak oxygen uptake assessed by cardiopulmonary exercise testing; secondary end points included muscular strength, 6-minute walk distance, and quality of life (Kansas City Cardiomyopathy Questionnaire and Medical Outcomes Study 12-Item Short-Form Health Survey questionnaires). Safety was assessed by documenting training-related adverse events, prosthesis, and renal function. RESULTS Significant changes in favor of TG were observed for peak oxygen uptake (group difference, 3.7 mL/min per kg [95% CI, 1.1-6.3; P=.007]), muscular strength (bench press, 6 kg [95% CI, 3-10; P=.002]; rowing, 7 kg [95% CI, 3-11; P<.001]; pulldown, 9 kg [95% CI, 4-14; P=.001]; shoulder press, 5 kg [95% CI, 1-8; P=.008]; leg press, 17 kg [95% CI 6-28; P=.005]), components of quality of life (Kansas City Cardiomyopathy Questionnaire physical limitation, 19.2 [95% CI, 4.1-34.2; P=.015]; symptom burden, 12.3 [95% CI, 0.5-24.0; P=.041]; clinical summary, 12.4 [3.4-21.4; P=.009]), but not for other questionnaire subscales and 6-minute walk distance (15 m [95% CI, -23 to 53; P=.428]). Three dropouts unrelated to exercise occurred (TG=2; usual care,=1); prosthesis and renal function were not affected by the exercise intervention. CONCLUSIONS In patients after TAVI, exercise training appears safe and highly effective with respect to improvements in exercise capacity, muscular strength, and quality of life. CLINICAL TRIAL REGISTRATION Clinicaltrials.govNCT01935297.
Collapse
Affiliation(s)
- Axel Pressler
- Department of Prevention, Rehabilitation and Sports Medicine, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.
| | - Jeffrey W Christle
- Department of Prevention, Rehabilitation and Sports Medicine, Klinikum rechts der Isar, Technische Universität München, Munich, Germany
| | - Benjamin Lechner
- Department of Prevention, Rehabilitation and Sports Medicine, Klinikum rechts der Isar, Technische Universität München, Munich, Germany
| | - Viola Grabs
- Department of Prevention, Rehabilitation and Sports Medicine, Klinikum rechts der Isar, Technische Universität München, Munich, Germany
| | - Bernhard Haller
- Institute for Medical Statistics and Epidemiology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany
| | - Ina Hettich
- Department of Pneumology, University Hospital Freiburg, Freiburg, Germany
| | - David Jochheim
- Cardiology Department, Munich University Clinic, Munich, Germany
| | - Julinda Mehilli
- Cardiology Department, Munich University Clinic, Munich, Germany; DZHK (German Center for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany
| | - Rüdiger Lange
- Clinic for Cardiovascular Surgery, German Heart Center Munich, Munich, Germany
| | - Sabine Bleiziffer
- Clinic for Cardiovascular Surgery, German Heart Center Munich, Munich, Germany
| | - Martin Halle
- Department of Prevention, Rehabilitation and Sports Medicine, Klinikum rechts der Isar, Technische Universität München, Munich, Germany; DZHK (German Center for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany; Else Kröner-Fresenius-Zentrum am Klinikum rechts der Isar, Technische Universität München, Munich, Germany
| |
Collapse
|
248
|
Dahya V, Xiao J, Prado CM, Burroughs P, McGee D, Silva AC, Hurt JE, Mohamed SG, Noel T, Batchelor W. Computed tomography-derived skeletal muscle index: A novel predictor of frailty and hospital length of stay after transcatheter aortic valve replacement. Am Heart J 2016; 182:21-27. [PMID: 27914496 DOI: 10.1016/j.ahj.2016.08.016] [Citation(s) in RCA: 43] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/11/2015] [Accepted: 08/24/2016] [Indexed: 01/06/2023]
Abstract
To determine the prevalence of low skeletal muscle mass in patients undergoing transcatheter aortic valve replacement (TAVR) and whether skeletal muscle mass measured from preoperative computed tomography (CT) images provides value in predicting postoperative length of stay (LOS). BACKGROUND There are limited data on the use of body composition as a frailty measure in TAVR patients and no studies have determined if this measure predicts LOS. METHODS We studied 104 consecutive patients who underwent TAVR at Tallahassee Memorial Hospital from 2012 to 2016. Patient demographics, standard frailty measures (hand grip, albumin, and 5-m walk test), clinical comorbidities, echocardiographic data, and Valve Academic Research Consortium II major complications were recorded prospectively. Skeletal muscle index (SMI) [skeletal muscle mass cross-sectional area at L3/height2] was measured from CT images using Slice-O-Matic software (Tomovision, Montreal, Quebec, Canada). Clinical outcomes were assessed and multivariate methods used to determine predictors of LOS. RESULTS Sarcopenia was prevalent in men (83%) and women (56%). Patients who suffered from a major complication had significantly longer length of stay (13 vs 4.6days, P<.0001). Skeletal muscle index correlated with age, sex, body mass index, handgrip strength, and previous coronary artery bypass graft surgery, but not major complications. A multivariate model including all univariate predictors of LOS showed SMI, major complications, transapical access, atrial fibrillation, and chronic obstructive pulmonary syndrome as independent predictors of LOS. For every 14-cm2/m2 increase in SMI, there was a 1-day reduction in LOS. None of the standard measures of frailty predicted LOS. CONCLUSIONS Skeletal muscle index, a measure of sarcopenia readily determined from pre-TAVR CT scans, independently predicts TAVR LOS better than standard frailty testing. Further evaluation of SMI as a frailty measure after TAVR and other cardiovascular procedures is warranted.
Collapse
|
249
|
Sex-Based Differences in Outcomes With Transcatheter Aortic Valve Therapy. J Am Coll Cardiol 2016; 68:2733-2744. [DOI: 10.1016/j.jacc.2016.10.041] [Citation(s) in RCA: 120] [Impact Index Per Article: 13.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/27/2016] [Revised: 09/26/2016] [Accepted: 10/03/2016] [Indexed: 11/24/2022]
|
250
|
The impact of frailty on failure-to-rescue in geriatric trauma patients. J Trauma Acute Care Surg 2016; 81:1150-1155. [DOI: 10.1097/ta.0000000000001250] [Citation(s) in RCA: 62] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
|